

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Autoimmune lymphoproliferative syndrome: more... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-1928/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-1928" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Autoimmune lymphoproliferative syndrome: more than a FAScinating disease" />
    
            <meta name="og:title" content="F1000Research Article: Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.">
            <meta name="og:description" content="Read the latest article version by Karen Bride, David Teachey, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12471">
            <meta name="article-id" content="11545">
            <meta name="dc.title" content="Autoimmune lymphoproliferative syndrome: more than a FAScinating disease">
            <meta name="dc.description" content="Autoimmune lymphoproliferative syndrome (ALPS) is an inherited syndrome characterized by abnormal lymphocyte survival caused by failure of apoptotic mechanisms to maintain lymphocyte homeostasis. This failure leads to the clinical manifestations of non-infectious and non-malignant lymphadenopathy, splenomegaly, and autoimmune pathology, most commonly, autoimmune cytopenias. Since ALPS was first characterized in the early 1990s, insights in disease biology have improved both diagnosis and management of this syndrome. Sirolimus is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients in need of chronic treatment. This review highlights practical clinical considerations for the diagnosis and management of ALPS. Further studies could reveal new proteins and regulatory pathways that are critical for lymphocyte activation and apoptosis.">
            <meta name="dc.subject" content="autoimmune,cytopenias,sirolimus,MMF,double negative T cells,lymphoproliferative disease,Fas/FasL,Targeted therapy">
            <meta name="dc.creator" content="Bride, Karen">
            <meta name="dc.creator" content="Teachey, David">
            <meta name="dc.date" content="2017/11/01">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11545.1">
            <meta name="dc.source" content="F1000Research 2017 6:1928">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="autoimmune">
            <meta name="prism.keyword" content="cytopenias">
            <meta name="prism.keyword" content="sirolimus">
            <meta name="prism.keyword" content="MMF">
            <meta name="prism.keyword" content="double negative T cells">
            <meta name="prism.keyword" content="lymphoproliferative disease">
            <meta name="prism.keyword" content="Fas/FasL">
            <meta name="prism.keyword" content="Targeted therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/11/01">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="1928">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11545.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-1928">
            <meta name="citation_title" content="Autoimmune lymphoproliferative syndrome: more than a FAScinating disease">
            <meta name="citation_abstract" content="Autoimmune lymphoproliferative syndrome (ALPS) is an inherited syndrome characterized by abnormal lymphocyte survival caused by failure of apoptotic mechanisms to maintain lymphocyte homeostasis. This failure leads to the clinical manifestations of non-infectious and non-malignant lymphadenopathy, splenomegaly, and autoimmune pathology, most commonly, autoimmune cytopenias. Since ALPS was first characterized in the early 1990s, insights in disease biology have improved both diagnosis and management of this syndrome. Sirolimus is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients in need of chronic treatment. This review highlights practical clinical considerations for the diagnosis and management of ALPS. Further studies could reveal new proteins and regulatory pathways that are critical for lymphocyte activation and apoptosis.">
            <meta name="citation_description" content="Autoimmune lymphoproliferative syndrome (ALPS) is an inherited syndrome characterized by abnormal lymphocyte survival caused by failure of apoptotic mechanisms to maintain lymphocyte homeostasis. This failure leads to the clinical manifestations of non-infectious and non-malignant lymphadenopathy, splenomegaly, and autoimmune pathology, most commonly, autoimmune cytopenias. Since ALPS was first characterized in the early 1990s, insights in disease biology have improved both diagnosis and management of this syndrome. Sirolimus is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients in need of chronic treatment. This review highlights practical clinical considerations for the diagnosis and management of ALPS. Further studies could reveal new proteins and regulatory pathways that are critical for lymphocyte activation and apoptosis.">
            <meta name="citation_keywords" content="autoimmune,cytopenias,sirolimus,MMF,double negative T cells,lymphoproliferative disease,Fas/FasL,Targeted therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Karen Bride">
            <meta name="citation_author_institution" content="Division of Oncology, The Children&rsquo;s Hospital of Philadelphia, Philadelphia, PA, USA">
            <meta name="citation_author" content="David Teachey">
            <meta name="citation_author_institution" content="Division of Oncology, The Children&rsquo;s Hospital of Philadelphia, Philadelphia, PA, USA">
            <meta name="citation_publication_date" content="2017/11/01">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="1928">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11545.1">
            <meta name="citation_firstpage" content="1928">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-1928/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-1928.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12471 /> <input type=hidden id=articleId name=articleId value=11545 /> <input type=hidden id=xmlUrl value="/articles/6-1928/v1/xml"/> <input type=hidden id=xmlFileName value="-6-1928-v1.xml"> <input type=hidden id=article_uuid value=9a6f9850-4203-4481-9072-bb8039743b55 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Autoimmune lymphoproliferative syndrome: more than a FAScinating disease"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11545.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11545.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-1928"
  },
  "headline": "Autoimmune lymphoproliferative syndrome: more than a FAScinating disease",
  "datePublished": "2017-11-01T10:52:53",
  "dateModified": "2017-11-01T10:52:53",
  "author": [
    {
      "@type": "Person",
      "name": "Karen Bride"
    },    {
      "@type": "Person",
      "name": "David Teachey"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Autoimmune lymphoproliferative syndrome (ALPS) is an inherited syndrome characterized by abnormal lymphocyte survival caused by failure of apoptotic mechanisms to maintain lymphocyte homeostasis. This failure leads to the clinical manifestations of non-infectious and non-malignant lymphadenopathy, splenomegaly, and autoimmune pathology, most commonly, autoimmune cytopenias. Since ALPS was first characterized in the early 1990s, insights in disease biology have improved both diagnosis and management of this syndrome. Sirolimus is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients in need of chronic treatment. This review highlights practical clinical considerations for the diagnosis and management of ALPS. Further studies could reveal new proteins and regulatory pathways that are critical for lymphocyte activation and apoptosis."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-1928",
            "name": "Autoimmune lymphoproliferative syndrome: more than a FAScinating disease"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Autoimmune lymphoproliferative syndrome: more than a FAScinating disease </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12471 data-id=11545 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11545.1" data-recommended="" data-doi="10.12688/f1000research.11545.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-1928/v1/pdf?article_uuid=9a6f9850-4203-4481-9072-bb8039743b55" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11545-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11545-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11545-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bride K and Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1928 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11545.1" target=_blank>https://doi.org/10.12688/f1000research.11545.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11545-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11545 id=track-article-signin-11545 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11545?target=/articles/6-1928">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12471 /> <input name=articleId type=hidden value=11545 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Autoimmune lymphoproliferative syndrome: more than a FAScinating disease</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Karen Bride,&nbsp;</span><span class=""><a href="mailto:teacheyd@email.chop.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David Teachey</span></a><a href="https://orcid.org/0000-0001-7373-8987" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7373-8987</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Karen Bride,&nbsp;</span><span class=""><a href="mailto:teacheyd@email.chop.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David Teachey</span></a><a href="http://orcid.org/0000-0001-7373-8987" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7373-8987</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 01 Nov 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11545.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Oncology, The Children&rsquo;s Hospital of Philadelphia, Philadelphia, PA, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=26913-27480></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=26914-27481></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=26915-27484></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Autoimmune lymphoproliferative syndrome (ALPS) is an inherited syndrome characterized by abnormal lymphocyte survival caused by failure of apoptotic mechanisms to maintain lymphocyte homeostasis. This failure leads to the clinical manifestations of non-infectious and non-malignant lymphadenopathy, splenomegaly, and autoimmune pathology, most commonly, autoimmune cytopenias. Since ALPS was first characterized in the early 1990s, insights in disease biology have improved both diagnosis and management of this syndrome. Sirolimus is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients in need of chronic treatment. This review highlights practical clinical considerations for the diagnosis and management of ALPS. Further studies could reveal new proteins and regulatory pathways that are critical for lymphocyte activation and apoptosis. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> autoimmune,cytopenias,sirolimus,MMF,double negative T cells,lymphoproliferative disease,Fas/FasL,Targeted therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> David Teachey (<a href="mailto:teacheyd@email.chop.edu">teacheyd@email.chop.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> David Teachey </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This manuscript was supported by funding from Cures within Reach and the Barbara Brodsky Foundation. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Bride K and Teachey D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bride K and Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1928 (<a href="https://doi.org/10.12688/f1000research.11545.1" target=_blank>https://doi.org/10.12688/f1000research.11545.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 01 Nov 2017, <b>6</b>(F1000 Faculty Rev):1928 (<a href="https://doi.org/10.12688/f1000research.11545.1" target=_blank>https://doi.org/10.12688/f1000research.11545.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 01 Nov 2017, <b>6</b>(F1000 Faculty Rev):1928 (<a href="https://doi.org/10.12688/f1000research.11545.1" target=_blank>https://doi.org/10.12688/f1000research.11545.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d507e158>Background</h2><p class="" id=d507e161>Autoimmune lymphoproliferative syndrome (ALPS) is a rare condition characterized by defective apoptotic mechanisms that disrupt lymphocyte homeostasis<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. Apoptotic defects lead to a lymphoproliferative disease with clinical manifestations, including lymphadenopathy, hepatomegaly, splenomegaly, autoimmune disease, and secondary malignancies. Characterized initially in the 1990s, ALPS was noted in a cohort of patients with chronic lymphoproliferation and an increased number of a characteristic T-cell population termed “double negative T cells” (DNTs)<sup><a href="#ref-5">5</a></sup>. DNTs express CD3 and the alpha/beta T-cell receptor (TCRα/β) but lack CD4 and CD8. Other signature laboratory abnormalities in ALPS include elevated levels of interleukin 10 (IL-10), IL-18, vitamin B<sub>12</sub>, soluble FAS ligand (sFASL), and IgG in plasma or sera as well as i<i>n vitro</i> evidence of defective FAS-mediated apoptosis<i></i><sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a>,<a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. Significant advances in our understanding of the pathophysiology of ALPS led to improved diagnostic criteria and eventually targeted therapeutic strategies, including the mammalian target of rapamycin (mTOR) inhibitor sirolimus (also known as rapamycin or Rapamune). Though considered a rare disease, ALPS is now more commonly diagnosed, as more clinicians have become aware of the disorder. Over the past 10–15 years, improvements in genomic technologies have led to the description of a number of ALPS-like autoimmune and lymphoproliferative disorders, including <i>RAS</i>-associated leukoproliferative disease (RALD); caspase-8 deficiency state (CEDS); <i>p110delta</i> activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI or activated PI3K delta syndrome); <i>CTLA-4</i> haploinsufficiency with autoimmune infiltration (CHAI); gain-of-function (GOF) signal transducer and activator of transcription 3 (<i>STAT3</i>) mutations; and lipopolysaccharide-responsive vesicle trafficking, beach and anchor containing (<i>LRBA</i>) deficiency with autoantibodies, regulatory T-cell defects, autoimmune infiltration, and enteropathy (LATAIE) (<a href="#T1">Table 1</a>)<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Collectively, these rare conditions clinically resemble ALPS and often are misdiagnosed as ALPS. Management for these conditions may include targeted therapy or hematopoietic stem cell transplant (HSCT) or both; therefore, it is crucial that clinicians understand and recognize how to diagnose and manage ALPS and these ALPS-like disorders.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Autoimmune lymphoproliferative syndrome (ALPS)-related syndromes that are potentially similar to but genetically distinct from ALPS or meet characteristics of ALPS with undetermined genetic defects (ALPS-U).</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d507e233 class=n-a></a><thead><a name=d507e235 class=n-a></a><tr><a name=d507e237 class=n-a></a><th align=left colspan=2 rowspan=1 valign=top><a name=d507e239 class=n-a></a>ALPS-related syndromes</th><th colspan=2 rowspan=1><a name=d507e242 class=n-a></a></th><th colspan=2 rowspan=1><a name=d507e244 class=n-a></a></th></tr><tr><a name=d507e247 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d507e249 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e252 class=n-a></a>Nomenclature</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e255 class=n-a></a>Mutation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e258 class=n-a></a>Clinical features</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e261 class=n-a></a>Laboratory biomarkers</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e265 class=n-a></a>Potential targeted<br class=br>therapies</th></tr></thead><tbody><a name=d507e272 class=n-a></a><tr><a name=d507e274 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e276 class=n-a></a>Ras-associated<br class=br>autoimmune<br class=br>leukoproliferative<br class=br>disorder<sup><a href="#ref-65">65</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e288 class=n-a></a>RALD </td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e291 class=n-a></a>Germline or somatic <i>NRAS</i> and<br class=br><i>KRAS</i> mutations<br class=br>RAS markedly decreases Bim<br class=br>protein expression leading to<br class=br>impaired lymphoid withdrawal<br class=br>and T-cell receptor (TCR)-<br class=br>induced apoptosis.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e312 class=n-a></a>Primary immunodeficiency disorder<br class=br>of defective apoptosis leading<br class=br>to lymphadenopathy, massive<br class=br>splenomegaly, increased circulating<br class=br>B cells, hypergammaglobulinemia,<br class=br>and autoimmunity increased risk for<br class=br>hematopoietic malignancies.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e328 class=n-a></a>Persistent absolute or<br class=br>relative monocytosis,<br class=br>hypergammaglobulinemia,<br class=br>B lymphocytosis<br class=br><br class=br>Does not exhibit elevated<br class=br>“double negative T cells”<br class=br>(DNTs), vitamin B<sub>12</sub><br class=br><br class=br>Activating somatic<br class=br>mutations in <i>KRAS</i> or <i>NRAS</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e358 class=n-a></a>Mitogen-activated<br class=br>pathway kinase (MAPK)<br class=br>inhibitors (for example,<br class=br>trametinib), mammalian<br class=br>target of rapamycin<br class=br>(mTOR) inhibitors<br class=br>(sirolimus, everolimus)</td></tr><tr><a name=d507e375 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e377 class=n-a></a>Dianzani autoimmune<br class=br>lymphoproliferative<br class=br>disease<sup><a href="#ref-32">32</a>,<a href="#ref-66">66</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e390 class=n-a></a>DALD </td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e393 class=n-a></a>No causative genes identified<br class=br><br class=br>Overexpression of the cytokine<br class=br>osteopontin<sup><a href="#ref-67">67</a></sup><br class=br><br class=br>Perforin<sup><a href="#ref-68">68</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e410 class=n-a></a>Exhibit autoimmunity, lymphoproliferation,<br class=br>splenomegaly, and defective Fas without<br class=br>expansion of DNT cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e417 class=n-a></a>Absent DNTs<br class=br><br class=br>FAS resistance but without<br class=br><i>FAS</i> or <i>FASL</i> mutations</td><td colspan=1 rowspan=1><a name=d507e431 class=n-a></a></td></tr><tr><a name=d507e434 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e436 class=n-a></a>Caspase-8 deficiency<br class=br>state<sup><a href="#ref-38">38</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e444 class=n-a></a>CEDS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e447 class=n-a></a>Loss-of-function mutation in<br class=br><i>CASP8</i> thought to play a dual<br class=br>role in the induction of the<br class=br>nuclear factor-kappa B (NF-κB)<br class=br>transcription factor during<br class=br>lymphocyte activation as well<br class=br>as in apoptosis mediated by the<br class=br>Fas death-inducing signaling<br class=br>complex (DISC) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e469 class=n-a></a>Exhibit lymphoproliferation and<br class=br>apoptosis defects observed in ALPS but<br class=br>manifests immunodeficiency rather than<br class=br>autoimmunity; recurrent sinopulmonary<br class=br>infections<sup><a href="#ref-69">69</a></sup>. Increased risk for malignancy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e484 class=n-a></a>Serum Ig levels, antibody<br class=br>function, lymphocyte<br class=br>activation<br class=br><br class=br>Defective activation of T, B<br class=br>and natural killer (NK) cells<br class=br><br class=br><i>CASP8</i> deficiency</td><td colspan=1 rowspan=1><a name=d507e503 class=n-a></a></td></tr><tr><a name=d507e506 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e508 class=n-a></a>Fas-associated death<br class=br>domain deficiency<sup><a href="#ref-70">70</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e516 class=n-a></a><i>FADD</i><br class=br>deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e522 class=n-a></a>Autosomal recessive (AR) <i>FADD</i><br class=br>deficiency </td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e529 class=n-a></a>Characterized by severe bacterial and<br class=br>viral infections, congenital heart defects<br class=br>and recurrent episodes of fever, liver<br class=br>dysfunction, and seizures</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e538 class=n-a></a><i>FADD</i> deficiency</td><td colspan=1 rowspan=1><a name=d507e544 class=n-a></a></td></tr><tr><a name=d507e547 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e549 class=n-a></a>Common variable<br class=br>immunodeficiency 9<sup><a href="#ref-71">71</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e557 class=n-a></a>Protein kinase<br class=br>C delta<br class=br>(<i>PRKCD</i>)<br class=br>deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e569 class=n-a></a>AR <i>PRKCD</i> primary<br class=br>immunodeficiency </td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e577 class=n-a></a>Characterized by recurrent infections,<br class=br>lymphadenopathy, hepatosplenomegaly,<br class=br>autoimmunity, and NK cell dysfunction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e584 class=n-a></a>IL-10 overexpression by<br class=br>B cells</td><td colspan=1 rowspan=1><a name=d507e590 class=n-a></a></td></tr><tr><a name=d507e594 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e596 class=n-a></a>Activated PI3K delta<br class=br>syndrome<sup><a href="#ref-29">29</a>,<a href="#ref-48">48</a>,<a href="#ref-72">72</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e610 class=n-a></a>APDS, also<br class=br>known as PASLI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e615 class=n-a></a>Heterozygous gain-of-function<br class=br>mutations in <i>PI<sub>3</sub>KCD</i> or <i>PI<sub>3</sub>KR1</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e632 class=n-a></a>Recurrent respiratory infections and<br class=br>increased susceptibility to viral infections<br class=br>with both B- and T-cell defects</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e639 class=n-a></a>Decreased naïve T cells,<br class=br>low IgG, IgA, and normal or<br class=br>elevated IgM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e647 class=n-a></a>mTOR inhibitors, PI3K<br class=br>inhibitors</td></tr><tr><a name=d507e653 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e655 class=n-a></a>X-linked<br class=br>immunodeficiency with<br class=br>magnesium defect,<br class=br>Epstein-Barr virus (EBV)<br class=br>infection and neoplasia<sup><a href="#ref-28">28</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e669 class=n-a></a>XMEN disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e672 class=n-a></a>Loss-function mutations in<br class=br>magnesium transporter 1<br class=br>(<i>MAGT1</i>); X-linked</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e682 class=n-a></a>Chronic high-level EBV with increased<br class=br>EBV-infected B cells and increased<br class=br>susceptibility to EBV-associated<br class=br>lymphomas</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e691 class=n-a></a>Mg deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e695 class=n-a></a>Magnesium</td></tr><tr><a name=d507e699 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e701 class=n-a></a>Gain-of-function<br class=br>mutations in signal<br class=br>transducer and activator<br class=br>of transcription 1 defect</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e710 class=n-a></a>GOF <i>STAT1</i><br class=br>defect</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e717 class=n-a></a><i>STAT1-</i>gain of function mutation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e722 class=n-a></a>Chronic mucocutaneous candidiasis,<br class=br>recurrent <i>Staphylococcus aureus</i><br class=br>infections, cerebral aneurysms, and<br class=br>multiple autoimmune features</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e733 class=n-a></a>Decreased TH17 response</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e737 class=n-a></a>JAK/STAT inhibitors (for<br class=br>example, Ruxolitinib)</td></tr><tr><a name=d507e743 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e745 class=n-a></a>Gain-of-function<br class=br>mutations in signal<br class=br>transducer and activator<br class=br>of transcription 3<sup><a href="#ref-31">31</a>,<a href="#ref-48">48</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e760 class=n-a></a>GOF <i>STAT3</i>-<br class=br>mutations</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e768 class=n-a></a><i>STAT3</i>-gain of function mutation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e773 class=n-a></a>Lymphoproliferation and childhood-onset<br class=br>autoimmunity thought to result from<br class=br>dysregulated cytokine signaling and<br class=br>interstitial lung disease </td><td colspan=1 rowspan=1><a name=d507e782 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e785 class=n-a></a>Anti-IL-6R monoclonal<br class=br>antibody (Tocilizumab)</td></tr><tr><a name=d507e791 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e793 class=n-a></a>Cytotoxic T lymphocyte<br class=br>antigen (<i>CTLA4</i>)<br class=br>haploinsufficiency with<br class=br>autoimmune infiltration<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e811 class=n-a></a>CHAI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e814 class=n-a></a>Heterozygous loss-of-function<br class=br>mutations in <i>CTLA4</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e821 class=n-a></a>Hypogammaglobulinemia and<br class=br>autoantibody-mediated cytopenias,<br class=br>lymphadenopathy, splenomegaly, organ-<br class=br>specific autoimmunity, and lymphocytic<br class=br>infiltration of non-lymphoid organs<br class=br><br class=br>CHAI more commonly seen in older<br class=br>children or young adults while disease<br class=br>onset in LATAIE is typically earlier. </td><td colspan=1 rowspan=1><a name=d507e840 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e843 class=n-a></a>CTLA4-Ig fusion drug<br class=br>(Abatacept)<br class=br><br class=br>mTOR inhibitors</td></tr><tr><a name=d507e852 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e854 class=n-a></a>Common variable<br class=br>immune deficiency<br class=br>caused by defect in<br class=br>lipopolysaccharide-<br class=br>responsive and beige-<br class=br>like anchor protein<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-48">48</a></sup><br class=br><br class=br>LRBA deficiency<br class=br>with autoantibodies,<br class=br>regulatory T-cell defects,<br class=br>autoimmune infiltration,<br class=br>and enteropathy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e888 class=n-a></a><i>LRBA</i><br class=br>deficiency<br class=br><br class=br>LATAIE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e897 class=n-a></a><i>LRBA</i> encodes the<br class=br>lipopolysaccharide-responsive<br class=br>and beige-like anchor protein,<br class=br>thought to regulate CTLA4<br class=br>(cytotoxic T lymphocyte antigen-4)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e910 class=n-a></a>Antibody deficiency, infection,<br class=br>autoimmunity, and lymphoproliferation,<br class=br>often linked with enteropathy or<br class=br>inflammatory bowel disease. Lymphocyte<br class=br>infiltration also seen in lungs and brain </td><td colspan=1 rowspan=1><a name=d507e921 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e924 class=n-a></a>CTLA4-Ig fusion drugs<br class=br><br class=br>Hydroxycholoroquine or<br class=br>chloroquine<br class=br><br class=br>mTOR inhibitors</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d507e940 class=n-a></a><p id=d507e942> The majority of these syndromes have been defined based on the genomic defect with associated symptoms. GOF, gain-of-function.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e951>Pathophysiology</h2><p class="" id=d507e954>Normal control of lymphocyte proliferation and immune tolerance is essential for both host defense and protection against self-directed immune attack<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. This process is most often mediated by the cell surface receptor FAS, a member of the tumor necrosis factor receptor (TNFR) superfamily, also termed CD95/APO1 (<a href="#f1">Figure 1</a>)<sup><a href="#ref-10">10</a></sup>. Similar to others in the TNFR family, FAS operates as a homotrimeric complex and is activated by the cognate FAS ligand (FASL), another homotrimeric protein complex homologous to TNF<sup><a href="#ref-12">12</a></sup>. Following ligation, the intracellular death domain of FAS nucleates an extended complex of the Fas-associated death domain (FADD) adaptor protein with caspase-8 and -10. These caspases subsequently undergo a signaling cascade of downstream effector caspases and other targets that eventually lead to proteolysis, DNA degradation, and apoptosis. Mutations in genes encoding even a single defective subunit in FAS, FASL, FADD, and CASP10 have all been linked to ALPS and have been classified according to their genetic defect (<a href="#T2">Table 2</a>).</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12471/a0518cf1-0c21-45e1-b876-1c05ed9fa6f0_figure1.gif"><img alt="a0518cf1-0c21-45e1-b876-1c05ed9fa6f0_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12471/a0518cf1-0c21-45e1-b876-1c05ed9fa6f0_figure1.gif"></a><div class=caption><h3>Figure 1. Fas apoptotic pathway.</h3><p id=d507e988>In an attempt to downregulate an immune response, activated B and T cells upregulate FAS while activated T cells will activate FAS ligand (FASL). These cells will interact and trigger a caspase cascade, leading to proteolysis, DNA degradation, and apoptosis. This FAS-mediated pathway is part of the extrinsic apoptotic pathway. In contrast, mitochondrial-induced apoptosis after cellular stress is part of the intrinsic apoptotic pathway.</p></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Prior classification of genetic mutations related to autoimmune lymphoproliferative syndrome, according to the underlying genetic defect.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d507e1006 class=n-a></a><thead><a name=d507e1008 class=n-a></a><tr><a name=d507e1010 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d507e1012 class=n-a></a>Type</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e1015 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e1018 class=n-a></a>Mutation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d507e1021 class=n-a></a>Proportion of ALPS<br class=br>attributed to mutation<br class=br>of the gene</th></tr></thead><tbody><a name=d507e1030 class=n-a></a><tr><a name=d507e1032 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1034 class=n-a></a>Type 0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1037 class=n-a></a>ALPS-FAS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1040 class=n-a></a>Germline homozygous mutations in <i>FAS</i></td><td colspan=1 rowspan=1><a name=d507e1045 class=n-a></a></td></tr><tr><a name=d507e1048 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1050 class=n-a></a>Type Ia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1053 class=n-a></a>ALPS-FAS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1056 class=n-a></a>Germ-line heterozygous mutations in <i>FAS</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1061 class=n-a></a>65–70%</td></tr><tr><a name=d507e1065 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1067 class=n-a></a>Type Im</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1070 class=n-a></a>ALPS sFAS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1073 class=n-a></a>Somatic mutation in <i>FAS</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1078 class=n-a></a>15–20%</td></tr><tr><a name=d507e1082 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1084 class=n-a></a>Type Ib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1087 class=n-a></a>ALPS-FASLG</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1090 class=n-a></a>Germline mutations in FASL (<i>TNFSF6</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1096 class=n-a></a>&lt;1%</td></tr><tr><a name=d507e1100 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1102 class=n-a></a>Type IIa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1105 class=n-a></a>ALPS caspase 10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1108 class=n-a></a>Germline mutation in <i>CASP10</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1113 class=n-a></a>3–6%</td></tr><tr><a name=d507e1118 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1120 class=n-a></a>Type III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1123 class=n-a></a>ALPS-U</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1126 class=n-a></a>No identifiable mutation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e1129 class=n-a></a>20%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d507e1137 class=n-a></a><p id=d507e1139> Prior classification of genetic mutations related to autoimmune lymphoproliferative syndrome, according to the underlying genetic defect<sup><a href="#ref-6">6</a>,<a href="#ref-73">73</a></sup>. The majority of patients with autoimmune lymphoproliferative syndrome (ALPS) carry heterozygous germline or somatic <i>FAS</i> mutations or both.</p></div></div></div><p class="" id=d507e1155>The role of FAS in maintaining lymphocyte homeostasis and peripheral immune tolerance to prevent autoimmunity was initially elucidated by studies of mice with deficient fas<i></i> (MRL/<i>lpr</i> knockout mice) or fasL (MRL/<i>gld</i>)<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. These mice were discovered to have massive DNT cell proliferation that accumulated in secondary lymphoid organs, in addition to hypergammaglobulinemia and glomerulonephritis<sup><a href="#ref-13">13</a>,<a href="#ref-15">15</a></sup>. Although <i>FAS</i> was identified as the critical gene underlying disease pathogenesis, the presence of the <i>FAS</i> mutation alone does not equal clinical disease manifestations. This was recently described in a comprehensive report by the National Institute of Allergy and Infectious Diseases (NIAID) of 150 ALPS-FAS patients and 63 healthy <i>FAS</i> mutation–positive family-member controls<sup><a href="#ref-16">16</a></sup>. While the predominant genetic mechanism of ALPS resides in the apoptosis-signaling complex by abnormal FAS proteins, healthy mutation-positive controls demonstrate apoptosis defects almost as severely as affected patients but can be clinically asymptomatic without elevated DNTs, sFASL, and IL-10. Moreover, some of the healthy mutation-positive controls had biomarker evidence of disease but were asymptomatic whereas other family members had very mild disease (for example, mildly low platelet count or very mild anemia). These data suggest that <i>FAS</i> mutations causing cellular apoptosis abnormalities alone are not sufficient to cause clinical ALPS. One hypothesis suggests that modifier genes as well as environmental factors may be involved<sup><a href="#ref-17">17</a></sup>. Furthermore, the clinical penetrance of heterozygous <i>FAS</i> mutations (described as 70% in the presence of one mutation) suggests that a “second hit” may be required for disease onset<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. The precise mechanism underlying disease pathogenesis remains unclear but may be related to the development of DNTs, which are significantly elevated in patients with ALPS but lower in healthy controls.</p><p class="" id=d507e1213>Although the exact mechanism of <i>FAS</i> mutations leading to the accumulation of DNTs may not be clear, multiple studies demonstrate that DNTs are associated with a hyperactive mTOR pathway<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>. We initially hypothesized that hyperactive mTOR signaling may drive the abnormal proliferation of DNTs, based on our work in preclinical ALPS models demonstrating that the mTOR inhibitor sirolimus was effective in reducing DNTs, lymphadenopathy, splenomegaly, and autoantibodies in the <i>lpr</i> mice<sup><a href="#ref-20">20</a></sup>. We have since demonstrated the effective use of sirolimus in humans in a multi-institutional clinical trial of patients with ALPS refractory to standard therapy<sup><a href="#ref-21">21</a></sup>. Furthermore, DNTs were reduced in patients with ALPS yet normal T-cell subsets were relatively spared with sirolimus. Subsequently, Völkl <i>et al</i>. validated the critical role of dysregulated mTOR signaling demonstrating that DNT cells of patients with ALPS have enhanced mitotic activity and hyperactive mTOR signaling<sup><a href="#ref-19">19</a></sup>. Following treatment with sirolimus <i>in vitro</i>, DNT cells from these patients with ALPS demonstrate reduced proliferation and increased apoptosis. Furthermore, mTOR inhibition abolished expression of IL-10 in ALPS DNTs, which not only blocks proliferation but also selectively induces apoptosis in abnormally differentiated DNT cells. In contrast, DNT cells from patients whose ALPS was treated with mycophenolate mofetil (MMF) (also known as CellCept) retained the abnormal differentiation and mitotic activity, corroborating that mTOR is a more relevant target and suggesting sirolimus as a potentially superior therapeutic option compared with MMF.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e1251>Genetics</h2><p class="" id=d507e1254>Although ALPS can be caused by single-gene mutations, it is a complex human disease with variable disease penetrance and severity. Over 90 unique mutations are registered in the database of ALPS mutations at the NIAID<sup><a href="#ref-22">22</a></sup>. One of the first well-characterized human genetic diseases of apoptosis, ALPS is most commonly associated with autosomal dominant transmission of heterozygous germline mutations in <i>FAS</i>, described in up to about 70% of genetically defined ALPS<i></i><sup><a href="#ref-13">13</a>,<a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. The next most common mutation includes somatic <i>FAS</i> mutations (10% of patients), or mutations that affect the FAS signaling apparatus known as the death-inducing signaling complex (DISC)<sup><a href="#ref-16">16</a>,<a href="#ref-19">19</a>,<a href="#ref-25">25</a></sup>. Mutations in genes encoding <i>FASL</i> and <i>CASP10</i> have been implicated in ALPS termed ALPS-FASL (&lt;1%) and ALPS-CASP10 (&lt;1%), respectively, but are much more rare<sup><a href="#ref-16">16</a>,<a href="#ref-22">22</a></sup>. As mentioned, some patients with ALPS have multiple mutations, including germline mutations in one <i>FAS</i> allele and somatic mutations in the other.</p><p class="" id=d507e1305>Older classification schemas designated the different genomic subtypes of ALPS with a numerical system (0–III) (<a href="#T2">Table 2</a>)<sup><a href="#ref-2">2</a></sup>. In 2009, a consensus conference at the National Institutes of Health (NIH) revised the nomenclature to mirror the World Health Organization system that uses a gene name–based classification for hematologic malignancies<sup><a href="#ref-2">2</a></sup>. The mode of inheritance for the majority of types is autosomal dominant (ALPS-FAS, ALPS-FASLG, and ALPS-CASP10). ALPS-FAS and ALPS-FASLG can also be caused by biallelic pathogenic variants inherited in an autosomal recessive manner (<a href="#T2">Table 2</a>). ALPS-sFAS and ALPS-FAS patients are clinically indistinguishable.</p><p class="" id=d507e1322>A number of ALPS-like syndromes with identifiable mutations not directly seen in ALPS are continually being discovered and described<sup><a href="#ref-26">26</a></sup>. Recent whole exome sequencing and whole genome sequencing have revealed new potential genetic drivers in the subgroup of ALPS with undetermined genetic defects (ALPS-U). <a href="#T1">Table 1</a> lists a number of candidate genes—including <i>KRAS</i>, <i>NRAS</i>, <i>CTLA4</i>, <i>LRBA</i>, <i>PI3kinase</i> (PI3κ), <i>MAGT1</i>, <i>STAT3</i>, and <i>TNFAIP3</i> (TNF-α–induced protein 3)—that have all been linked with ALPS-like features<sup><a href="#ref-26">26</a>–<a href="#ref-32">32</a></sup>. It is beyond the scope of this review to discuss all of these ALPS-like syndromes in detail. <a href="#T1">Table 1</a> provides key differences and considerations for diagnosis and management. A key point to emphasize is that these other syndromes are rare and, as is often the case in newly identified rare diseases, the published disease phenotype is based on a select number of patients who came to medical attention for a unifying clinical feature. As larger studies are performed, we may see that the published phenotype does not resemble the “actual” most common phenotype of the disease; for example, clinical outliers may represent the index cases. Furthermore, families with multiple mutations in ALPS and ALPS-like genes (<i>CASP10</i> and <i>sFAS</i><sup><a href="#ref-33">33</a></sup> and <i>FAS</i>, <i>XIAP</i>, and <i>UNC13D</i><sup><a href="#ref-34">34</a></sup>) have been described leading to complex phenotypes<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Interestingly, the genetic alterations in the Fas pathway influence not only the development of ALPS but also the phenotype—by the concurrent effect of other mutations. Therefore, it is important to have a low index of suspicion for ALPS and other ALPS-like disorders in children with unexplained lymphoproliferation or chronic autoimmune disease. Given the power of whole exome sequencing of DNA from patients with ALPS, we are likely to be at the precipice of having a better understanding of the pathogenesis of diseases with immune dysregulation and identifying a number of potential candidate genes that have features similar to those of ALPS.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e1400>Clinical characteristics and epidemiology</h2><p class="" id=d507e1403>In spite of the unifying gene defects found in ALPS, there is a wide range of disease symptoms and variability in the defining characteristics among individuals and subtypes of ALPS. The prevalence and true incidence of ALPS are unknown, likely since many instances remain undiagnosed or misdiagnosed. In fact, recent studies have shown that it may be more common than previously thought, given recognition of adult-onset disease and patients with a mild phenotype<sup><a href="#ref-16">16</a></sup>. Young patients with autoimmune manifestations early in life can be a diagnostic clue for underlying ALPS. Patients with ALPS can often manifest more severe disease characteristics in early childhood which resolve by adolescence and young adulthood<sup><a href="#ref-35">35</a></sup>. Thus, in retrospect, these patients with resolved clinical manifestations that were unexplained in the past likely carried the diagnosis of ALPS, leading to marked underestimation of true prevalence. There is also no known difference in severity of disease between sex, in spite of data suggesting a male preponderance. ALPS has been diagnosed in both sexes and in diverse racial backgrounds<sup><a href="#ref-16">16</a></sup>.</p><p class="" id=d507e1418>At some point in their lives, patients with ALPS, by definition, have clinically identifiable chronic lymphoproliferation, which manifests as adenopathy (&gt;95% of patients) and splenomegaly (&gt;90%) or hepatomegaly (40–50%)<sup><a href="#ref-16">16</a>,<a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. The earliest and primary clinical manifestation of ALPS is chronic, diffuse lymphadenopathy, with or without splenomegaly or hepatomegaly or both, in an otherwise healthy child. The majority of patients develop lymphoproliferation at a young age (median age of 11.5 months), often in the absence of associated constitutional symptoms<sup><a href="#ref-16">16</a></sup>. The lymphoproliferation tends to improve with age and can wax and wane randomly but commonly worsens in adolescence before resolving in most patients in their early 20s. More than 80% of patients with ALPS experience a prolonged period of enlarged palpable and non-tender lymph nodes.</p><p class="" id=d507e1435>Patients with ALPS can have lymphocytosis that affects T and B cells but not natural killer cells. Although absolute numbers of total T and B cells are increased, the pronounced lymphoproliferation has been attributed mostly to the accumulation of the pathognomonic DNTs<sup><a href="#ref-19">19</a></sup>. The biologic hallmark of ALPS, DNTs are mature post-thymic T cells that express a rearranged CD3/TCRα/β receptor but lack CD4 or CD8 co-receptors<sup><a href="#ref-5">5</a></sup>. These cells are distinct from TCRγ/δ, which are normally CD4<sup>−</sup>CD8<sup>−</sup>, and can be increased non-specifically in ALPS and other conditions<sup><a href="#ref-38">38</a></sup>. In healthy adults, the DNT cells constitute less than 1% of peripheral lymphocytes, whereas in ALPS, DNTs can comprise more than 40% of lymphocytes<sup><a href="#ref-38">38</a></sup>. In addition to ALPS, DNTs have been found in the peripheral blood of patients with other autoimmune diseases like systemic lupus erythematosus, mixed connective tissue disease, and antinuclear antibody–positive oligoarticular or polyarticular juvenile idiopathic arthritis; however, their precise function or pathogenic role is not clear<sup><a href="#ref-5">5</a></sup>. In ALPS, in contrast to these other autoimmune diseases, the elevations of DNT cells are above 3% of total lymphocytes (or more than 5% of T lymphocyte cells) and this is rarely seen in conditions other than ALPS<sup><a href="#ref-2">2</a>,<a href="#ref-39">39</a></sup>. They have long been thought to arise from chronically active or senescent CD8<sup>+</sup> T cells unable to undergo apoptosis because of defective Fas signaling. Recent studies have since challenged that notion with evidence of Ki-67 staining by immunohistochemistry of lymph nodes of patients with ALPS, demonstrating a unique phenotype with expression of both memory and markers of senescence, which also exhibit hyperactive mTOR signaling<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d507e1479>Autoimmunity is the second most common clinical manifestation, affecting over 70% of patients<sup><a href="#ref-1">1</a>,<a href="#ref-13">13</a>,<a href="#ref-40">40</a></sup>. The most common autoimmune manifestation is autoimmune destruction of blood cells in one or more cell lineages (that is, autoimmune hemolytic anemia, autoimmune thrombocytopenia, or neutropenia or a combination of these). This finding can be associated with either an elevated or decreased serum IgG. Although the presence of the cytopenias may not be present at the time of initial diagnosis, the evidence of autoimmune cytopenias—including Coombs-positive autoimmune hemolytic anemia and autoimmune thrombocytopenia with or without the association of autoantibodies—can be detected before manifestations of the autoimmune disease clinically<sup><a href="#ref-35">35</a></sup>. Autoimmune cytopenias may vary from asymptomatic laboratory abnormalities to multi-lineage cytopenia-related life-threatening illness<sup><a href="#ref-40">40</a></sup>. In many patients, the autoimmune cytopenias often require medical intervention—ranging from treatment for periodic disease flares after infections to chronic therapy. Autoimmune cytopenias can also fluctuate in severity and type over time (for example, affecting one cell line and changing to another with age). Similar to lymphoproliferation, autoimmune cytopenias can improve with age, although they are less likely to resolve completely in adulthood<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d507e1505>Other autoimmune disease manifestations outside of cytopenias can also be seen in patients with ALPS. These can occur in approximately 10–20% of patients with ALPS and can affect nearly any organ system. The most common are skin rashes (typically but not exclusively urticarial). Other autoimmune manifestations include immune-mediated pulmonary fibrosis, autoimmune thyroiditis, uveitis, Guillain-Barré syndrome, hepatitis, nephritis, gastritis, pancreatitis, colitis, transverse myelitis, cerebellar ataxia, myocarditis, and arthritis<sup><a href="#ref-37">37</a></sup>. Of note, many of these co-morbid autoimmune manifestations are most commonly described in patients with ALPS-U. Some of these patients with ALPS-U do not have ALPS but have an ALPS-like disorder as previously mentioned (<a href="#T1">Table 1</a>). For example, at our institution, a number of patients who met diagnostic criteria for ALPS-U were later identified to have mutations in <i>LRBA</i>, <i>CTLA4</i>, and <i>PI<sub>3</sub>Kδ</i> (Teachey <i>et al</i>., unpublished data).</p><p class="" id=d507e1531>Patients with ALPS also have an increased risk of secondary malignancies, most commonly both Hodgkin and non-Hodgkin lymphoma<sup><a href="#ref-41">41</a></sup>. This risk is estimated to be up to 60 to 150 times that of the general population and is most prevalent in <i>FAS</i> mutant ALPS<sup><a href="#ref-16">16</a>,<a href="#ref-41">41</a></sup>. Interestingly, the increased risk of lymphoma was once consistently documented only in <i>FAS</i> mutant ALPS and even higher among patients with dominant-interfering mutations in <i>FAS</i> but lower in patients with <i>FAS</i> haploinsufficiency<sup><a href="#ref-37">37</a>,<a href="#ref-42">42</a></sup>. Recently, a family with homozygous <i>FASLG</i> mutation was reported, presenting the first documented case of peripheral T-cell lymphoma<sup><a href="#ref-43">43</a></sup>. Together, these data suggest that there may be a correlation between the degree of disruption of the apoptotic signaling complex and the propensity to develop lymphoma<sup><a href="#ref-16">16</a>,<a href="#ref-43">43</a></sup>. Healthy family members with <i>FAS</i> mutations but no clinical evidence of ALPS are at increased risk for lymphomagenesis, underscoring the role of <i>FAS</i> as a tumor-suppressor gene. Co-morbid factors that have also been proposed to increase this risk include defective T-cell surveillance, Epstein-Barr virus (EBV) infection, and defective B-cell apoptosis<sup><a href="#ref-16">16</a>,<a href="#ref-44">44</a></sup>. However, general consensus concludes that abnormal immune regulation and defective FAS-mediated apoptosis provide an expanded lymphoid pool at risk for clonal transformation<sup><a href="#ref-44">44</a></sup>. The temporal delay (cumulative incidence increases with age) between the onset of ALPS manifestations and that of lymphoma also suggests a requirement for additional oncogenic events such as mutations in <i>C-MYC</i>, <i>CCND1</i>, <i>BCL2</i>, and <i>BCL6</i><sup><a href="#ref-45">45</a></sup>. In fact, increased somatic hypermutation has been noted in cells with FAS-induced apoptotic defects, leading to self-reactive specificities, and also in dysfunctional immunoglobulins or in double-strand breaks that cannot be repaired by the normal DNA repair machinery.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e1616>Differential diagnosis: whom to test?</h2><p class="" id=d507e1619>No specific laboratory abnormality alone is diagnostic of ALPS. Given its heterogeneous phenotype, the constellation of lymphadenopathy, organomegaly, and autoimmunity can be found in other malignant, infectious, autoimmune, and rheumatologic conditions. For example, primary immunodeficiencies with autoimmune and other cytopenias, namely in the context of immune dysregulation, can have similar, if not overlapping, characteristics<sup><a href="#ref-30">30</a></sup>. Other lymphoproliferative disorders—such as Castleman disease, Rosai-Dorfman disease, X-linked lymphoproliferative disease, Dianzani autoimmune lymphoproliferative disease and Kikuchi-Fujimoto disease—can have clinical features similar to those of ALPS (<a href="#T1">Table 1</a>)<sup><a href="#ref-4">4</a></sup>. RALD with somatic pathogenic variants of <i>NRAS</i> and <i>KRAS</i>, CEDS, FADD deficiency, <i>PI3κ</i>, <i>LRBA</i>, <i>CTLA4</i>, GOF germline <i>STAT3</i> mutations, and common variable immunodeficiency 9 (<i>PRKCD</i> deficiency) are considered ALPS-like disorders since they cause similar phenotypes, but the pathogenic gene variants may not be within the FAS/FASL pathway. Identification of the potential underlying mutation, as in GOF <i>STAT3</i> mutations, not only expands the clinical spectrum of ALPS-like disorders but also provides the rationale for the use of inhibitors of the pathway when the underlying defect has been identified<sup><a href="#ref-31">31</a>,<a href="#ref-46">46</a>,<a href="#ref-47">47</a></sup>.</p><p class="" id=d507e1669>Overlapping syndromes have also been reported among combined variable immunodeficiency (CVID), Evans syndrome (ES), and ALPS. In fact, a subset of patients with ALPS have co-morbid CVID; therefore, distinguishing between these two diseases can be difficult<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. Autoimmune hematological abnormalities, specifically cytopenias, are the most common of all autoimmune manifestations of CVID<sup><a href="#ref-50">50</a></sup>. While most patients with ALPS have elevated IgG, they can also have decreased IgG levels, more characteristic of CVID. Similarly, ES, defined by autoimmune destruction of at least two hematologic cell types, can have a constellation of overlapping clinical findings, as in ALPS, and has been reported to precede the clinical and immunological phenotype of CVID<sup><a href="#ref-49">49</a>,<a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. We have previously described that over one third of patients with diagnosed ES actually fulfilled the criteria and diagnosis of ALPS<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>. The underlying pathophysiology of ES is unknown but is thought to be secondary to generalized immune dysregulation. Therefore, ES is a diagnosis of exclusion, and other confounding disorders, like chronic EBV, must be ruled out before establishing the diagnosis<sup><a href="#ref-43">43</a>,<a href="#ref-54">54</a></sup>. Hyper IgM syndrome and <i>WAS</i>-related disorders that include Wiskott-Aldrich syndrome, X-linked thrombocytopenia, and X-linked congenital neutropenia can also have features similar to those of ALPS.</p><p class="" id=d507e1711>Certainly, continued discovery of genetic mutations in the subgroup of patients with ALPS-U will likely reveal other potential overlapping syndromes to ALPS. Although some of the criteria for ALPS are defined, further study is clearly needed.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e1718>Diagnosis</h2><p class="" id=d507e1721>Given the heterogeneity in clinical features, the diagnosis of ALPS is based on clinical observation and laboratory abnormalities, including elevated DNT cells in peripheral blood. Significant advances in our understanding of the disease since its initial identification have prompted revision of diagnostic criteria (<a href="#T3">Table 3</a>) and classification defined currently by the NIH consensus statement in 2009<sup><a href="#ref-2">2</a>,<a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Current 2010 clinical criteria for the diagnosis of autoimmune lymphoproliferative syndrome.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d507e1748 class=n-a></a><thead><a name=d507e1750 class=n-a></a><tr><a name=d507e1752 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d507e1753 class=n-a></a>Required criteria</th></tr></thead><tbody><a name=d507e1757 class=n-a></a><tr><a name=d507e1759 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1760 class=n-a></a>Chronic (&gt;6 months), non-malignant, non-infectious lymphadenopathy or splenomegaly or both</td></tr><tr><a name=d507e1763 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1764 class=n-a></a>Elevated CD3<sup>+</sup>TCRab<sup>+</sup>CD4<sup>−</sup>CD8<sup>−</sup> “double negative T cells” (DNT) cells &gt; 1.5% of total lymphocytes<br class=br>or 2.5% of CD3<sup>+</sup> lymphocytes with normal or elevated lymphocyte counts</td></tr><tr><a name=d507e1785 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d507e1786 class=n-a></a>Accessory: primary</th></tr><tr><a name=d507e1789 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1790 class=n-a></a>Defective lymphocyte apoptosis</td></tr><tr><a name=d507e1793 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1794 class=n-a></a>Somatic or germline mutation in FAS, FAS ligand gene (FASLG), or caspase-10 gene (CASP10)</td></tr><tr><a name=d507e1798 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d507e1799 class=n-a></a>Accessory: secondary</th></tr><tr><a name=d507e1802 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1803 class=n-a></a>Elevated plasma soluble FAS ligand (sFASL) (&gt;200 pg/mL) or elevated plasma interleukin-10<br class=br>(IL-10) levels or elevated serum or plasma vitamin B<sub>12</sub> levels or elevated plasma IL-18 levels</td></tr><tr><a name=d507e1811 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1812 class=n-a></a>Typical immunohistological findings as reviewed by an experienced hematopathologist</td></tr><tr><a name=d507e1815 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1816 class=n-a></a>Autoimmune cytopenias and elevated IgG levels</td></tr><tr><a name=d507e1819 class=n-a></a><td colspan=1 rowspan=1><a name=d507e1820 class=n-a></a>Family history of a non-malignant/non-infectious lymphoproliferation with or without autoimmunity</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d507e1827 class=n-a></a><p id=d507e1829> Table adapted from Oliveira <i>et al</i>.<sup><a href="#ref-2">2</a></sup>. A definitive diagnosis of autoimmune lymphoproliferative syndrome (ALPS) comprises the required criteria plus one primary accessory criterion. Probable diagnosis of ALPS includes the required criteria with one secondary accessory.</p></div></div></div><p class="" id=d507e1842>The three classic diagnostic signs of ALPS are chronic lymphadenopathy and splenomegaly, a functional defect in lymphocyte apoptosis, and an increase in DNT cells<sup><a href="#ref-2">2</a></sup>. Based on the consensus statement, for the diagnosis of ALPS to be established, a patient has to meet both required criteria and one primary accessory criterion (<a href="#T3">Table 3</a>). Lymphoproliferation must be chronic (&gt;6 months) and affect two distinct nodal regions (with or without splenomegaly) while excluding neoplastic and infectious etiologies. The pathognomonic DNTs must be elevated, exceeding 1.5% of total lymphocytes or 2.5% of T lymphocytes. Importantly, this criterion is specific to normal or elevated lymphocyte counts since the relative distribution of DNT cells in lymphopenia is not accurately known and may be falsely elevated<sup><a href="#ref-2">2</a>,<a href="#ref-13">13</a>,<a href="#ref-26">26</a></sup>. Additional accessory criteria are further divided into primary and secondary categories. Presumably to encompass a larger number of similar novel immune disorders that mimic ALPS, the revised diagnostic criteria distinguish probable from definitive ALPS diagnosis, including one secondary accessory criterion rather than one primary accessory criterion (as in definitive ALPS). Some patients with probable ALPS have an ALPS-like disorder and should be tested for these conditions. If these other disorders have been ruled out, then patients with probable ALPS should be treated similarly to patients with definitive ALPS. As new ALPS-like syndromes are identified, it is important to consider and evaluate for these conditions among those with probable ALPS or ALPS-U or both.</p><p class="" id=d507e1862>In a recent study following individuals with ALPS over 20 years compared with healthy mutation-positive relatives, Price <i>et al</i>. suggest that a novel biomarker signature, including elevated levels of soluble IL-10, IL-18, sFASL, and vitamin B<sub>12</sub> measured in plasma/serum, can make a presumptive diagnosis of ALPS<sup><a href="#ref-16">16</a></sup>. Although this profile may not substitute for molecular analyses, since other conditions like CVID or ES can have a similar profile (namely elevated vitamin B<sub>12</sub> and sFASL), this is an inexpensive set of tests that can prompt further testing, especially when molecular or genetic analysis may not be readily available. However, new insights and broader understanding of ALPS and ALPS-U highlight the need for continued revision of current guidelines to facilitate prompt diagnosis while recognizing the evolving complexity of the ALPS diagnosis arrived at through many potential pathways. Moreover, the overlapping clinical features and newly identified novel immunodysregulatory syndromes that may underlie overlapping symptoms suggest the need for prompt consideration by clinicians and potentially more advanced diagnostic tools, including both traditional assays or more modern techniques, such as next-generation sequencing or whole exome sequencing.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e1881>Management</h2><p class="" id=d507e1884>The management of ALPS focuses on treatment of disease manifestations and complications. The only known cure is HSCT. However, because of the risks associated with HSCT, it is often performed only in those with very severe clinical phenotypes who are refractory to immune suppression<sup><a href="#ref-37">37</a></sup>. The majority of patients with ALPS can live relatively normal healthy lives without the need for HSCT. Therefore, the bulk of management focuses on monitoring for and treatment of disease-specific complications, including lymphoproliferation and autoimmune cytopenias. The overall prognosis for patients with ALPS is good but depends on steroid-sparing management of cytopenias. Nearly 50–60% of patients with ALPS require immunosuppressive therapy to control autoimmunity, but the overwhelming majority of these patients can be managed with single-agent immune suppression<sup><a href="#ref-37">37</a></sup>. A careful risk-benefit evaluation is needed prior to exposing any patient to medications with long-term co-morbidities.</p><p class="" id=d507e1895>First-line treatment of ALPS often includes high-dose intravenous corticosteroids and intravenous immunoglobulin (IVIgG)<sup><a href="#ref-13">13</a>,<a href="#ref-26">26</a></sup>. Many patients often respond well to corticosteroids (1–2 mg/kg). Although in the short term the toxicities of high-dose steroids can be mild (including hypertension, hyperglycemia, irritability, and weight gain), the long-term toxicities are serious and potentially severe<sup><a href="#ref-40">40</a></sup>. Furthermore, since ALPS is a chronic disease, many patients need chronic treatment<sup><a href="#ref-13">13</a>,<a href="#ref-40">40</a></sup>. As a result, at our center, we try to limit corticosteroid exposure, with a low threshold to transition quickly to steroid-sparing immune suppression.</p><p class="" id=d507e1916>IVIgG, in contrast, is less effective, and it has a poorer response among patients except those with single-lineage autoimmune thrombocytopenia<sup><a href="#ref-1">1</a>,<a href="#ref-6">6</a>,<a href="#ref-40">40</a></sup>. Similar to steroids, IVIgG can be quick-acting (within 48 hours) and well tolerated; however, the effect is short-lived, requiring repeated infusions. Anti-D immunoglobulin (WinRho) is often discouraged for isolated thrombocytopenia since many patients may be positive for the direct antiglobulin test with a risk for worse hemolysis with additional WinRho administration<sup><a href="#ref-1">1</a>,<a href="#ref-40">40</a></sup>. Isolated neutropenia, either acute or chronic and while not otherwise being managed on maintenance therapy, may benefit from granulocyte colony-stimulating factor. However, we would recommend treating these patients with autoimmune neutropenia only if they develop infections.</p><p class="" id=d507e1936>Management strategies such as splenectomy and rituximab are commonly employed for autoimmune disease but are relatively contraindicated in patients with ALPS, especially in light of other more effective common therapies. Rituximab, a monoclonal antibody against the CD20 molecule, has been used but with variable efficacy<sup><a href="#ref-48">48</a>,<a href="#ref-55">55</a></sup>. Most available data regarding efficacy of rituximab arise from retrospective studies of patients with autoimmune hemolytic anemia and immune thrombocytopenia (ITP)<sup><a href="#ref-55">55</a></sup>. Unlike patients with ITP, some patients with ALPS treated with rituximab have been shown to never recover normal B-cell function after its use, resulting in persistent hypogammaglobulinemia. In the absence of prospective trials, the true benefit of rituximab is not known, and there is the added risk of requiring lifetime IVIgG replacement. Thus, we believe that rituximab should be avoided unless other treatment approaches fail.</p><p class="" id=d507e1951>In the past, ALPS has also been treated with splenectomy to manage chronic refractory cytopenias. A number of studies have demonstrated that patients with ALPS who undergo splenectomy have an increased risk of pneumococcal sepsis despite vaccination and antimicrobial prophylaxis. Though considered in refractory cases who fail all available options, splenectomy has significant risks, is often ineffective, and rarely leads to permanent remissions<sup><a href="#ref-16">16</a>,<a href="#ref-56">56</a></sup>. In one report of patients with ALPS, 41% of splenectomized patients developed one or more episodes of sepsis, and there were six deaths due to overwhelming sepsis, which reinforces the recommendation to avoid splenectomy and consider second-line immunomodulatory agents to manage chronic cytopenias<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d507e1965>The two most commonly used immunomodulatory drugs for ALPS are MMF and sirolimus. MMF is metabolized in the body to mycophenolic acid (MPA) and inhibits inosine-5′-monophosphate dehydrogenase. MPA acts to cause a preferential reduction in guanosine nucleotides in T and B cells, thereby inhibiting proliferation<sup><a href="#ref-57">57</a></sup>. The administration of MMF, initially described in 2005, has proven to be an effective steroid-sparing agent in improving autoimmune cytopenias in approximately 80% of patients with ALPS, based on clinical trials<sup><a href="#ref-40">40</a>,<a href="#ref-58">58</a></sup>. Among its benefits are that MMF does not require therapeutic drug monitoring, does not have significant drug-drug interactions, and has a safe and tolerable side-effect profile. The most common side effects include diarrhea and neutropenia. In spite of measured improvements in autoimmune disease, MMF has not been observed to cause lymphocyte death or have any effect on lymphoproliferative disease or depletion of DNTs<sup><a href="#ref-40">40</a>,<a href="#ref-59">59</a></sup>. Moreover, some patients have partial responses, and in some patients the responses are not durable, requiring discontinuation of MMF or use of periodic steroid pulses during disease flares. As it is a well-tolerated agent that is effective in many patients, it is often used. Therefore, MMF is still recommended as a second-line agent, particularly in patients with mild to moderate autoimmune disease without clinically significant lymphoproliferation (<a href="#f2">Figure 2</a>). Of note, unlike corticosteroids, second-line therapies often take a few weeks and occasionally months to demonstrate benefit. Thus, patients often need to remain on steroids, which are slowly tapered. If tolerated, a 3- to 6-month trial should be performed before considering a second-line therapy a treatment failure.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12471/a0518cf1-0c21-45e1-b876-1c05ed9fa6f0_figure2.gif"><img alt="a0518cf1-0c21-45e1-b876-1c05ed9fa6f0_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12471/a0518cf1-0c21-45e1-b876-1c05ed9fa6f0_figure2.gif"></a><div class=caption><h3>Figure 2. Proposed algorithm of our approach to the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS) and associated mild-moderate and moderate-severe autoimmune disease, with or without clinically significant lymphoproliferation.</h3><p id=d507e1999>Adapted from George <i>et al</i>.<sup><a href="#ref-1">1</a></sup>. BID, twice daily.</p></div></div><p class="" id=d507e2013>Sirolimus is gaining increased recognition as an extremely effective agent in patients with ALPS. The primary rationale for using sirolimus stemmed from preclinical data from our group and others demonstrating dysregulation of mTOR signaling in patients with ALPS (<a href="#ref-6">6</a>, <a href="#ref-20">20</a>; see pathogenesis). These data have been further validated by other studies demonstrating that the pathognomonic DNT cells, as well as a subset of CD4 and CD8 T cells in patients with ALPS, are highly proliferative <i>in vivo</i> associated with a hyperactive mTOR pathway<sup><a href="#ref-19">19</a></sup>. Other potential benefits of mTOR inhibition are evidence of promotion and expansion of FoxP3<sup>+</sup> regulatory T cells (Tregs) both <i>in vitro</i> and <i>in vivo</i>, often implicated in autoimmune disease pathogenesis<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>.</p><p class="" id=d507e2046>We initially published the results using sirolimus with ALPS patients in a small retrospective cohort<sup><a href="#ref-59">59</a></sup>. Based on our preclinical data, the compelling rationale, and the results in our retrospective cohort, we opened a multi-center prospective clinical trial of sirolimus in patients with ALPS as well as children without ALPS and chronic autoimmune cytopenias. We demonstrated successful use of sirolimus in children with refractory autoimmune multi-lineage cytopenias, and 100% of patients with ALPS demonstrated a complete response (CR) or near CR. These included rapid durable improvements in autoimmune disease, lymphadenopathy, and splenomegaly within 1–3 months of starting sirolimus that were also durable, and follow-up extended up to 10 years<sup><a href="#ref-21">21</a></sup>. In addition to the ALPS patients treated in this study, we have also guided clinicians to treat 35 additional ALPS patients with sirolimus. These patients were diagnosed and treated at our institution, other centers in the United States, and 18 different countries, including nations on six continents (<a href="#T4">Table 4</a>). As these patients were not enrolled in our trial, we cannot present definitive data, but reportedly the majority (31 out of 35) of those patients achieved a durable CR with sirolimus.</p><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 4. An additional 35 patients from 18 different countries successfully used sirolimus for patients with autoimmune lymphoproliferative syndrome but were not enrolled on the study.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d507e2071 class=n-a></a><tbody><a name=d507e2073 class=n-a></a><tr><a name=d507e2075 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d507e2077 class=n-a></a>North America</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2080 class=n-a></a>USA</td></tr><tr><a name=d507e2084 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2086 class=n-a></a>Canada</td></tr><tr><a name=d507e2090 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2092 class=n-a></a>South America</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2095 class=n-a></a>Brazil</td></tr><tr><a name=d507e2099 class=n-a></a><td align=left colspan=1 rowspan=8 valign=top><a name=d507e2101 class=n-a></a>Europe</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2104 class=n-a></a>United Kingdom</td></tr><tr><a name=d507e2108 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2110 class=n-a></a>France</td></tr><tr><a name=d507e2115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2117 class=n-a></a>Germany</td></tr><tr><a name=d507e2121 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2123 class=n-a></a>Italy</td></tr><tr><a name=d507e2127 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2129 class=n-a></a>Kazakhstan</td></tr><tr><a name=d507e2133 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2135 class=n-a></a>Poland</td></tr><tr><a name=d507e2139 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2141 class=n-a></a>Spain</td></tr><tr><a name=d507e2145 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2147 class=n-a></a>Sweden</td></tr><tr><a name=d507e2152 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d507e2154 class=n-a></a>Africa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2157 class=n-a></a>Egypt</td></tr><tr><a name=d507e2161 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2163 class=n-a></a>South Africa</td></tr><tr><a name=d507e2167 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d507e2169 class=n-a></a>Asia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2172 class=n-a></a>China</td></tr><tr><a name=d507e2176 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2178 class=n-a></a>India</td></tr><tr><a name=d507e2182 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2184 class=n-a></a>Russia</td></tr><tr><a name=d507e2188 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2190 class=n-a></a>Middle East</td><td align=left colspan=1 rowspan=1 valign=top><a name=d507e2193 class=n-a></a>Saudi Arabia</td></tr></tbody></table></div><p class="" id=d507e2201>Additional published studies have since demonstrated similar results, suggesting moving sirolimus to upfront, first-line therapy<sup><a href="#ref-7">7</a>,<a href="#ref-19">19</a>,<a href="#ref-62">62</a></sup>. In a recent retrospective study of 18 patients with definitive ALPS (9 type 1a, eight sFAS, and one homozygous) treated with sirolimus as first-line therapy, the majority (94%, 17 out of 18 patients) experienced a CR. In addition, those with a CR had an associated normalization of known biomarkers, including DNTs and serum levels of vitamin B<sub>12</sub>, IL-10, and sFASL<sup><a href="#ref-7">7</a></sup>. MMF has similarly been shown to be effective in improving autoimmune cytopenias; however, unlike with sirolimus, many of these patients have partial responses prompting continued steroid use while others have relapsed<sup><a href="#ref-58">58</a>,<a href="#ref-63">63</a></sup>. Although some providers believe MMF should be trialed before sirolimus, Völkl <i>et al</i>. demonstrate that DNT cells treated with MMF retain abnormal differentiation and mitotic activity, indicating that sirolimus may be superior to MMF therapy<sup><a href="#ref-19">19</a></sup>. Furthermore, those patients who previously fail MMF often respond to sirolimus<sup><a href="#ref-63">63</a></sup>. It is uncertain whether sirolimus affects expansion or induces apoptosis of DNT cells or both, but its therapeutic efficacy suggests specific signaling requirements of mTOR in DNT cells. Furthermore, as previously mentioned, various studies have suggested that sirolimus promotes generation, expansion, and functionality of Tregs<sup><a href="#ref-61">61</a></sup>. However, the role of sirolimus in its contribution to modulating Tregs and their role in self-tolerance remain unclear.</p><p class="" id=d507e2244>As described by our multi-institutional prospective trial, we do not see any deficits in immune function in children with ALPS being treated with sirolimus<sup><a href="#ref-21">21</a></sup>. Importantly, none of those children was functionally immunosuppressed, as demonstrated by intact, unchanged functional immune activity in spite of prolonged treatment with sirolimus, without an increased incidence of opportunistic infection. Therefore, we do not recommend pneumocystis, antifungal, or antibacterial prophylaxis in ALPS patients on single-agent sirolimus. In contrast, we found that some patients with ALPS treated with MMF become profoundly lymphopenic.</p><p class="" id=d507e2251>One of the primary drawbacks of sirolimus is the need to monitor serum levels. We typically target our dosing to achieve a trough of 5–15 ng/mL, which often approximates to a dose of 2.5 mg/m<sup>2</sup> daily. Short-term side effects include mucositis, hypertension, and hypertriglyceridemia. We have not witnessed a correlation between targeted trough values and the presence of side effects; however, a dose-toxicity relationship has been shown in larger trials using sirolimus after solid organ transplant. In fact, we would like to highlight that most of the published data using sirolimus and other mTOR inhibitors are derived from combination therapies for graft rejection after transplant, or in malignancy, and only a handful of studies were directed to monotherapy. Other known issues with mTOR inhibitors include monitoring for hyperlidemia, decreased renal function, and myelosuppression. Oral mucositis can occur and is most pronounced in the first month of therapy and often resolves with time. Additionally, sirolimus pharmacokinetics, unlike MMF, can be altered by other multiple medications. Therefore, it is crucial to check for drug-drug interactions anytime a new medication is added. Patients who develop hyperlipidemia may need medical therapy with fish oil or a statin.</p><p class="" id=d507e2257>Our current proposed outline for our approach to patients with ALPS is shown in <a href="#f2">Figure 2</a>. We continue to recommend MMF in patients with mild to moderate autoimmune cytopenias that do not have clinically significant lymphoproliferation (organ compromise or hypersplenism). However, for patients who fail MMF, have moderate to severe autoimmune cytopenias, or have clinically significant lymphoproliferation, we recommend sirolimus. More and more frequently, our group and others are using sirolimus as first-line therapy. Third-line agents and their dosing are also described in <a href="#f2">Figure 2</a>.</p><p class="" id=d507e2266>More evidence is emerging supporting the use of sirolimus given its safety, tolerability, and most importantly efficacy. This is especially true in regard to ALPS-FAS patients and therefore may not be applicable to all patients. Certainly, the discovery of other pathogenic mechanisms of diseases like ALPS and other primary immunodeficiency and autoinflammatory disorders will likely reveal other specific immunomodulators that can target a particular arm or cytokine of the immune system, such as abatacept for <i>CTLA4 deficiency</i> (CHAI or LATAIE), tocilizumab in GOF STAT3 defects, or ruxolitinib for GOF STAT1 defects<sup><a href="#ref-48">48</a></sup> (<a href="#T1">Table 1</a>). Patients with PI<sub>3</sub>KCD GOF mutations have also been shown to have hyperactive mTOR activity, which has since prompted the use of sirolimus successfully for these patients<sup><a href="#ref-29">29</a>,<a href="#ref-48">48</a></sup>. Therefore, the new insights and increased attention of these diseases not only highlight the evolving complexity of ALPS and ALPS-like disorders but also emphasize the need for a broader understanding of the immune dysregulation underlining ALPS and ALPS-like disorders.</p><p class="" id=d507e2289>Beyond mTOR inhibitors and MMF, other agents trialed in patients with ALPS have been met with variable success. Pentostatin has been reported to have limited efficacy in some children with refractory cytopenias<sup><a href="#ref-13">13</a>,<a href="#ref-26">26</a>,<a href="#ref-48">48</a>,<a href="#ref-56">56</a>,<a href="#ref-58">58</a>,<a href="#ref-64">64</a></sup>. Pentostatin is an irreversible inhibitor of adenosine deaminase (ADA), which leads to the accumulation of intracellular deoxyadenosine-5′-triphosphate (d-ATP) that results in cytotoxicity and cell death by activation of apoptosis. Its use has been demonstrated to lead to improvement in hyperleukocytosis and decrease in the frequency of red cell and platelet transfusion. We have also successfully used a combination of methotrexate and sirolimus in ALPS-like patients who fail monotherapy sirolimus. Alternatively, we have treated highly refractory patients with autoimmune cytopenias with acute lymphoblastic leukemia maintenance-like therapy, including mercaptopurine and oral methotrexate with vincristine/prednisone pulses, for those experiencing flares. Finally, we have successfully treated some ALPS-like patients with the proteasome inhibitor bortezomib. Rarely, HSCT has been used for refractory patients. The experience overall is limited and careful consideration is needed given the significant risks associated with HSCT.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e2314>Surveillance</h2><p class="" id=d507e2317>Whereas non-malignant lymphoproliferative manifestations often regress or improve over time, the risk for development of lymphoma is lifelong. As previously mentioned, the risk of an ALPS patient developing Hodgkin lymphoma is estimated at 150 times that of the general population, and the risk of non-Hodgkin lymphoma is increased by 14-fold in those patients<sup><a href="#ref-4">4</a>,<a href="#ref-41">41</a></sup>. Given the fluctuation in size of chronic generalized adenopathy in patients with ALPS, these patients need close clinical observation; however, no imaging modality, including 18-fluorodeoxyglucose-positron emission tomography (FDG-PET), can accurately distinguish benign from malignant lymphoproliferation as ALPS lymphadenopathy is PET-avid<sup><a href="#ref-13">13</a></sup>. Furthermore, early diagnosis of lymphoma does not change clinical outcome. Therefore, we opt to evaluate for malignancy only in patients who have a significant change in disease pattern or who develop constitutional symptoms. Since progression to lymphoma is associated with monoclonal expansion of malignant lymphocytes, occasionally testing for clonality in lymphocyte subsets can help distinguish benign from malignant disease.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d507e2334>Summary</h2><p class="" id=d507e2337>Early recognition and diagnosis of ALPS are integral to successful management and treatment. Generally, the prognosis is good, especially in light of improved steroid-sparing agents, including sirolimus. Given robust preclinical and clinical evidence, we believe sirolimus should be considered as first-line therapy in many patients with ALPS, as it is an effective targeted therapy for the disease.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d507e1 class=n-a></a><h2 class=main-title id=d738>Competing interests</h2><p class=metadata-entry><a name=d507e90 class=n-a></a><p id=d507e91> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d507e1 class=n-a></a><h2 class=main-title id=d740>Grant information</h2><p>This manuscript was supported by funding from Cures within Reach and the Barbara Brodsky Foundation.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i></p></div><div class=back-section><a name=d507e2344 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d993>References</h2><div class="section ref-list"><a name=d507e2344 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d507e2351 class=n-a></a>George LA, Teachey DT: Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children. <i>Paediatr Drugs.</i> 2016; <b>18</b>(4): 261–72. <a target=xrefwindow id=d507e2359 href="http://www.ncbi.nlm.nih.gov/pubmed/27139496">PubMed Abstract </a> | <a target=xrefwindow id=d507e2362 href="http://dx.doi.org/10.1007/s40272-016-0175-3">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d507e2371 class=n-a></a>Oliveira JB, Bleesing JJ, Dianzani U, <i> et al.</i>: Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. <i>Blood.</i> 2010; <b>116</b>(14): e35–40. <a target=xrefwindow id=d507e2382 href="http://www.ncbi.nlm.nih.gov/pubmed/20538792">PubMed Abstract </a> | <a target=xrefwindow id=d507e2385 href="http://dx.doi.org/10.1182/blood-2010-04-280347">Publisher Full Text </a> | <a target=xrefwindow id=d507e2389 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2953894">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d507e2398 class=n-a></a>Teachey DT: Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management. <i>Clin Adv Hematol Oncol.</i> 2011; <b>9</b>(3): 233–5. <a target=xrefwindow id=d507e2406 href="http://www.ncbi.nlm.nih.gov/pubmed/21475130">PubMed Abstract </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d507e2415 class=n-a></a>Teachey DT: New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. <i>Curr Opin Pediatr.</i> 2012; <b>24</b>(1): 1–8. <a target=xrefwindow id=d507e2423 href="http://www.ncbi.nlm.nih.gov/pubmed/22157362">PubMed Abstract </a> | <a target=xrefwindow id=d507e2426 href="http://dx.doi.org/10.1097/MOP.0b013e32834ea739">Publisher Full Text </a> | <a target=xrefwindow id=d507e2429 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3673763">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d507e2438 class=n-a></a>Tarbox JA, Keppel MP, Topcagic N, <i> et al.</i>: Elevated double negative T cells in pediatric autoimmunity. <i>J Clin Immunol.</i> 2014; <b>34</b>(5): 594–9. <a target=xrefwindow id=d507e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/24760111">PubMed Abstract </a> | <a target=xrefwindow id=d507e2452 href="http://dx.doi.org/10.1007/s10875-014-0038-z">Publisher Full Text </a> | <a target=xrefwindow id=d507e2456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4047151">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d507e2466 class=n-a></a>Teachey DT, Seif AE, Grupp SA: Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). <i>Br J Haematol.</i> 2010; <b>148</b>(2): 205–16. <a target=xrefwindow id=d507e2474 href="http://www.ncbi.nlm.nih.gov/pubmed/19930184">PubMed Abstract </a> | <a target=xrefwindow id=d507e2477 href="http://dx.doi.org/10.1111/j.1365-2141.2009.07991.x">Publisher Full Text </a> | <a target=xrefwindow id=d507e2480 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2929682">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727193855"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2489 class=n-a></a>Klemann C, Esquivel M, Magerus-Chatinet A, <i> et al.</i>: Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome. <i>Haematologica.</i> 2017; <b>102</b>(2): e52–e56. <a target=xrefwindow id=d507e2500 href="http://www.ncbi.nlm.nih.gov/pubmed/27789675">PubMed Abstract </a> | <a target=xrefwindow id=d507e2503 href="http://dx.doi.org/10.3324/haematol.2016.153411">Publisher Full Text </a> | <a target=xrefwindow id=d507e2507 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5286954">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727193855">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d507e2520 class=n-a></a>Lo B, Fritz JM, Su HC, <i> et al.</i>: CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. <i>Blood.</i> 2016; <b>128</b>(8): 1037–42. <a target=xrefwindow id=d507e2531 href="http://www.ncbi.nlm.nih.gov/pubmed/27418640">PubMed Abstract </a> | <a target=xrefwindow id=d507e2534 href="http://dx.doi.org/10.1182/blood-2016-04-712612">Publisher Full Text </a> | <a target=xrefwindow id=d507e2538 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5000841">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725669971"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2547 class=n-a></a>Lo B, Zhang K, Lu W, <i> et al.</i>: AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. <i>Science.</i> 2015; <b>349</b>(6246): 436–40. <a target=xrefwindow id=d507e2558 href="http://www.ncbi.nlm.nih.gov/pubmed/26206937">PubMed Abstract </a> | <a target=xrefwindow id=d507e2561 href="http://dx.doi.org/10.1126/science.aaa1663">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725669971">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d507e2574 class=n-a></a>Lenardo MJ: Fas and the art of lymphocyte maintenance. <i>J Exp Med.</i> 1996; <b>183</b>(3): 721–4. <a target=xrefwindow id=d507e2582 href="http://www.ncbi.nlm.nih.gov/pubmed/8642275">PubMed Abstract </a> | <a target=xrefwindow id=d507e2585 href="http://dx.doi.org/10.1084/jem.183.3.721">Publisher Full Text </a> | <a target=xrefwindow id=d507e2588 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2192341">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d507e2597 class=n-a></a>Siegel RM, Frederiksen JK, Zacharias DA, <i> et al.</i>: Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. <i>Science.</i> 2000; <b>288</b>(5475): 2354–7. <a target=xrefwindow id=d507e2608 href="http://www.ncbi.nlm.nih.gov/pubmed/10875918">PubMed Abstract </a> | <a target=xrefwindow id=d507e2611 href="http://dx.doi.org/10.1126/science.288.5475.2354">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d507e2621 class=n-a></a>Lenardo MJ, Oliveira JB, Zheng L, <i> et al.</i>: ALPS-ten lessons from an international workshop on a genetic disease of apoptosis. <i>Immunity.</i> 2010; <b>32</b>(3): 291–5. <a target=xrefwindow id=d507e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/20346767">PubMed Abstract </a> | <a target=xrefwindow id=d507e2635 href="http://dx.doi.org/10.1016/j.immuni.2010.03.013">Publisher Full Text </a> | <a target=xrefwindow id=d507e2639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2858867">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d507e2648 class=n-a></a>Rao VK, Oliveira JB: How I treat autoimmune lymphoproliferative syndrome. <i>Blood.</i> 2011; <b>118</b>(22): 5741–51. <a target=xrefwindow id=d507e2656 href="http://www.ncbi.nlm.nih.gov/pubmed/21885601">PubMed Abstract </a> | <a target=xrefwindow id=d507e2659 href="http://dx.doi.org/10.1182/blood-2011-07-325217">Publisher Full Text </a> | <a target=xrefwindow id=d507e2662 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3228494">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d507e2671 class=n-a></a>Watanabe-Fukunaga R, Brannan CI, Copeland NG, <i> et al.</i>: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. <i>Nature.</i> 1992; <b>356</b>(6367): 314–7. <a target=xrefwindow id=d507e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/1372394">PubMed Abstract </a> | <a target=xrefwindow id=d507e2685 href="http://dx.doi.org/10.1038/356314a0">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725247590"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2694 class=n-a></a>Martina MN, Noel S, Saxena A, <i> et al.</i>: Double negative (DN) αβ T cells: misperception and overdue recognition. <i>Immunol Cell Biol.</i> 2015; <b>93</b>(3): 305–10. <a target=xrefwindow id=d507e2705 href="http://www.ncbi.nlm.nih.gov/pubmed/25420721">PubMed Abstract </a> | <a target=xrefwindow id=d507e2708 href="http://dx.doi.org/10.1038/icb.2014.99">Publisher Full Text </a> | <a target=xrefwindow id=d507e2712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4363250">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725247590">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718231009"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2725 class=n-a></a>Price S, Shaw PA, Seitz A, <i> et al.</i>: Natural history of autoimmune lymphoproliferative syndrome associated with <i>FAS</i> gene mutations. <i>Blood.</i> 2014; <b>123</b>(13): 1989–99. <a target=xrefwindow id=d507e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/24398331">PubMed Abstract </a> | <a target=xrefwindow id=d507e2743 href="http://dx.doi.org/10.1182/blood-2013-10-535393">Publisher Full Text </a> | <a target=xrefwindow id=d507e2746 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3968385">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718231009">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d507e2759 class=n-a></a>Rieux-Laucat F, Casanova JL: Immunology. Autoimmunity by haploinsufficiency. <i>Science.</i> 2014; <b>345</b>(6204): 1560–1. <a target=xrefwindow id=d507e2767 href="http://www.ncbi.nlm.nih.gov/pubmed/25258064">PubMed Abstract </a> | <a target=xrefwindow id=d507e2770 href="http://dx.doi.org/10.1126/science.1260791">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8317956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2780 class=n-a></a>Magerus-Chatinet A, Neven B, Stolzenberg MC, <i> et al.</i>: Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. <i>J Clin Invest.</i> 2011; <b>121</b>(1): 106–12. <a target=xrefwindow id=d507e2791 href="http://www.ncbi.nlm.nih.gov/pubmed/21183795">PubMed Abstract </a> | <a target=xrefwindow id=d507e2794 href="http://dx.doi.org/10.1172/JCI43752">Publisher Full Text </a> | <a target=xrefwindow id=d507e2798 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3007148">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8317956">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726303876"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2811 class=n-a></a>Völkl S, Rensing-Ehl A, Allgäuer A, <i> et al.</i>: Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. <i>Blood.</i> 2016; <b>128</b>(2): 227–38. <a target=xrefwindow id=d507e2822 href="http://www.ncbi.nlm.nih.gov/pubmed/27099149">PubMed Abstract </a> | <a target=xrefwindow id=d507e2825 href="http://dx.doi.org/10.1182/blood-2015-11-685024">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726303876">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d507e2838 class=n-a></a>Teachey DT, Obzut DA, Axsom K, <i> et al.</i>: Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). <i>Blood.</i> 2006; <b>108</b>(6): 1965–71. <a target=xrefwindow id=d507e2849 href="http://www.ncbi.nlm.nih.gov/pubmed/16757690">PubMed Abstract </a> | <a target=xrefwindow id=d507e2852 href="http://dx.doi.org/10.1182/blood-2006-01-010124">Publisher Full Text </a> | <a target=xrefwindow id=d507e2856 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1895548">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d507e2865 class=n-a></a>Bride KL, Vincent T, Smith-Whitley K, <i> et al.</i>: Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. <i>Blood.</i> 2016; <b>127</b>(1): 17–28. <a target=xrefwindow id=d507e2876 href="http://www.ncbi.nlm.nih.gov/pubmed/26504182">PubMed Abstract </a> | <a target=xrefwindow id=d507e2879 href="http://dx.doi.org/10.1182/blood-2015-07-657981">Publisher Full Text </a> | <a target=xrefwindow id=d507e2883 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4705607">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728024224"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e2892 class=n-a></a>Nabhani S, Hönscheid A, Oommen PT, <i> et al.</i>: A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome. <i>Clin Immunol.</i> 2014; <b>155</b>(2): 231–7. <a target=xrefwindow id=d507e2903 href="http://www.ncbi.nlm.nih.gov/pubmed/25451160">PubMed Abstract </a> | <a target=xrefwindow id=d507e2906 href="http://dx.doi.org/10.1016/j.clim.2014.10.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728024224">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d507e2919 class=n-a></a>Fisher GH, Rosenberg FJ, Straus SE, <i> et al.</i>: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. <i>Cell.</i> 1995; <b>81</b>(6): 935–46. <a target=xrefwindow id=d507e2930 href="http://www.ncbi.nlm.nih.gov/pubmed/7540117">PubMed Abstract </a> | <a target=xrefwindow id=d507e2933 href="http://dx.doi.org/10.1016/0092-8674(95)90013-6">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d507e2943 class=n-a></a>Rieux-Laucat F, Le Deist F, Hivroz C, <i> et al.</i>: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. <i>Science.</i> 1995; <b>268</b>(5215): 1347–9. <a target=xrefwindow id=d507e2954 href="http://www.ncbi.nlm.nih.gov/pubmed/7539157">PubMed Abstract </a> | <a target=xrefwindow id=d507e2957 href="http://dx.doi.org/10.1126/science.7539157">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d507e2966 class=n-a></a>Holzelova E, Vonarbourg C, Stolzenberg MC, <i> et al.</i>: Autoimmune lymphoproliferative syndrome with somatic <i>Fas</i> mutations. <i>N Engl J Med.</i> 2004; <b>351</b>(14): 1409–18. <a target=xrefwindow id=d507e2980 href="http://www.ncbi.nlm.nih.gov/pubmed/15459302">PubMed Abstract </a> | <a target=xrefwindow id=d507e2984 href="http://dx.doi.org/10.1056/NEJMoa040036">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d507e2993 class=n-a></a>Rao VK: Approaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative Syndrome. <i>Front Pediatr.</i> 2015; <b>3</b>: 65. <a target=xrefwindow id=d507e3001 href="http://www.ncbi.nlm.nih.gov/pubmed/26258116">PubMed Abstract </a> | <a target=xrefwindow id=d507e3004 href="http://dx.doi.org/10.3389/fped.2015.00065">Publisher Full Text </a> | <a target=xrefwindow id=d507e3007 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4508836">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726976532"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3016 class=n-a></a>Takagi M, Ogata S, Ueno H, <i> et al.</i>: Haploinsufficiency of <i>TNFAIP3</i> (<i>A20</i>) by germline mutation is involved in autoimmune lymphoproliferative syndrome. <i>J Allergy Clin Immunol.</i> 2017; <b>139</b>(6): 1914–22. <a target=xrefwindow id=d507e3034 href="http://www.ncbi.nlm.nih.gov/pubmed/27845235">PubMed Abstract </a> | <a target=xrefwindow id=d507e3037 href="http://dx.doi.org/10.1016/j.jaci.2016.09.038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726976532">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d507e3050 class=n-a></a>Li FY, Chaigne-Delalande B, Su H, <i> et al.</i>: XMEN disease: a new primary immunodeficiency affecting Mg<sup>2+</sup> regulation of immunity against Epstein-Barr virus. <i>Blood.</i> 2014; <b>123</b>(14): 2148–52. <a target=xrefwindow id=d507e3064 href="http://www.ncbi.nlm.nih.gov/pubmed/24550228">PubMed Abstract </a> | <a target=xrefwindow id=d507e3068 href="http://dx.doi.org/10.1182/blood-2013-11-538686">Publisher Full Text </a> | <a target=xrefwindow id=d507e3071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3975255">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d507e3080 class=n-a></a>Lucas CL, Chandra A, Nejentsev S, <i> et al.</i>: PI3Kδ and primary immunodeficiencies. <i>Nat Rev Immunol.</i> 2016; <b>16</b>(11): 702–14. <a target=xrefwindow id=d507e3091 href="http://www.ncbi.nlm.nih.gov/pubmed/27616589">PubMed Abstract </a> | <a target=xrefwindow id=d507e3094 href="http://dx.doi.org/10.1038/nri.2016.93">Publisher Full Text </a> | <a target=xrefwindow id=d507e3098 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5291318">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d507e3108 class=n-a></a>Seidel MG: Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. <i>Blood.</i> 2014; <b>124</b>(15): 2337–44. <a target=xrefwindow id=d507e3116 href="http://www.ncbi.nlm.nih.gov/pubmed/25163701">PubMed Abstract </a> | <a target=xrefwindow id=d507e3119 href="http://dx.doi.org/10.1182/blood-2014-06-583260">Publisher Full Text </a> | <a target=xrefwindow id=d507e3122 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4192747">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/724814019"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3131 class=n-a></a>Milner JD, Vogel TP, Forbes L, <i> et al.</i>: Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. <i>Blood.</i> 2015; <b>125</b>(4): 591–9. <a target=xrefwindow id=d507e3142 href="http://www.ncbi.nlm.nih.gov/pubmed/25359994">PubMed Abstract </a> | <a target=xrefwindow id=d507e3145 href="http://dx.doi.org/10.1182/blood-2014-09-602763">Publisher Full Text </a> | <a target=xrefwindow id=d507e3149 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4304103">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/724814019">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d507e3162 class=n-a></a>Dianzani U, Chiocchetti A, Ramenghi U: Role of inherited defects decreasing Fas function in autoimmunity. <i>Life Sci.</i> 2003; <b>72</b>(25): 2803–24. <a target=xrefwindow id=d507e3170 href="http://www.ncbi.nlm.nih.gov/pubmed/12697265">PubMed Abstract </a> | <a target=xrefwindow id=d507e3173 href="http://dx.doi.org/10.1016/S0024-3205(03)00196-6">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725760786"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3182 class=n-a></a>Martínez-Feito A, Melero J, Mora-Díaz S, <i> et al.</i>: Autoimmune lymphoproliferative syndrome due to somatic <i>FAS</i> mutation (ALPS-sFAS) combined with a germline caspase-10 (<i>CASP10</i>) variation. <i>Immunobiology.</i> 2016; <b>221</b>(1): 40–7. <a target=xrefwindow id=d507e3200 href="http://www.ncbi.nlm.nih.gov/pubmed/26323380">PubMed Abstract </a> | <a target=xrefwindow id=d507e3203 href="http://dx.doi.org/10.1016/j.imbio.2015.08.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725760786">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718113022"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3216 class=n-a></a>Boggio E, Aricò M, Melensi M, <i> et al.</i>: Mutation of <i>FAS</i>, <i>XIAP</i>, and <i>UNC13D</i> genes in a patient with a complex lymphoproliferative phenotype. <i>Pediatrics.</i> 2013; <b>132</b>(4): e1052–8. <a target=xrefwindow id=d507e3237 href="http://www.ncbi.nlm.nih.gov/pubmed/24043286">PubMed Abstract </a> | <a target=xrefwindow id=d507e3240 href="http://dx.doi.org/10.1542/peds.2012-1838">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718113022">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725508829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3253 class=n-a></a>Carneiro-Sampaio M, Coutinho A: Early-onset autoimmune disease as a manifestation of primary immunodeficiency. <i>Front Immunol.</i> 2015; <b>6</b>: 185. <a target=xrefwindow id=d507e3261 href="http://www.ncbi.nlm.nih.gov/pubmed/25999944">PubMed Abstract </a> | <a target=xrefwindow id=d507e3264 href="http://dx.doi.org/10.3389/fimmu.2015.00185">Publisher Full Text </a> | <a target=xrefwindow id=d507e3267 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4419659">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725508829">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d507e3281 class=n-a></a>Teachey DT, Greiner R, Seif A, <i> et al.</i>: Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. <i>Br J Haematol.</i> 2009; <b>145</b>(1): 101–6. <a target=xrefwindow id=d507e3292 href="http://www.ncbi.nlm.nih.gov/pubmed/19208097">PubMed Abstract </a> | <a target=xrefwindow id=d507e3295 href="http://dx.doi.org/10.1111/j.1365-2141.2009.07595.x">Publisher Full Text </a> | <a target=xrefwindow id=d507e3299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2819393">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d507e3308 class=n-a></a>Bleesing JJH, Nagaraj CB, Zhang K: Autoimmune Lymphoproliferative Syndrome. In <i>GeneReviews<sup>®</sup></i>. Adam MP, <i>et al.,</i> Editors. 1993, Seattle (WA). <a target=xrefwindow id=d507e3318 href="http://www.ncbi.nlm.nih.gov/pubmed/20301287">PubMed Abstract </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d507e3327 class=n-a></a>Su HC, Lenardo MJ: Genetic defects of apoptosis and primary immunodeficiency. <i>Immunol Allergy Clin North Am.</i> 2008; <b>28</b>(2): 329–51, ix. <a target=xrefwindow id=d507e3335 href="http://www.ncbi.nlm.nih.gov/pubmed/18424336">PubMed Abstract </a> | <a target=xrefwindow id=d507e3338 href="http://dx.doi.org/10.1016/j.iac.2008.01.002">Publisher Full Text </a> | <a target=xrefwindow id=d507e3341 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2671802">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d507e3350 class=n-a></a>Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, <i> et al.</i>: FAS-L, IL-10, and double-negative CD4<sup>–</sup> CD8<sup>–</sup> TCR alpha/beta<sup>+</sup> T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. <i>Blood.</i> 2009; <b>113</b>(13): 3027–30. <a target=xrefwindow id=d507e3371 href="http://www.ncbi.nlm.nih.gov/pubmed/19176318">PubMed Abstract </a> | <a target=xrefwindow id=d507e3374 href="http://dx.doi.org/10.1182/blood-2008-09-179630">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d507e3383 class=n-a></a>Teachey DT, Lambert MP: Diagnosis and management of autoimmune cytopenias in childhood. <i>Pediatr Clin North Am.</i> 2013; <b>60</b>(6): 1489–511. <a target=xrefwindow id=d507e3391 href="http://www.ncbi.nlm.nih.gov/pubmed/24237984">PubMed Abstract </a> | <a target=xrefwindow id=d507e3394 href="http://dx.doi.org/10.1016/j.pcl.2013.08.009">Publisher Full Text </a> | <a target=xrefwindow id=d507e3397 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5384653">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d507e3406 class=n-a></a>Straus SE, Jaffe ES, Puck JM, <i> et al.</i>: The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. <i>Blood.</i> 2001; <b>98</b>(1): 194–200. <a target=xrefwindow id=d507e3417 href="http://www.ncbi.nlm.nih.gov/pubmed/11418480">PubMed Abstract </a> | <a target=xrefwindow id=d507e3420 href="http://dx.doi.org/10.1182/blood.V98.1.194">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d507e3430 class=n-a></a>Bleesing JJ: Sorting out the causes of ALPS. <i>J Pediatr.</i> 2005; <b>147</b>(5): 571–4. <a target=xrefwindow id=d507e3438 href="http://www.ncbi.nlm.nih.gov/pubmed/16291343">PubMed Abstract </a> | <a target=xrefwindow id=d507e3441 href="http://dx.doi.org/10.1016/j.jpeds.2005.09.025">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725766912"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3450 class=n-a></a>Ruiz-García R, Mora S, Lozano-Sánchez G, <i> et al.</i>: Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel <i>FASLG</i> mutation. <i>Pediatr Res.</i> 2015; <b>78</b>(6): 603–8. <a target=xrefwindow id=d507e3464 href="http://www.ncbi.nlm.nih.gov/pubmed/26334989">PubMed Abstract </a> | <a target=xrefwindow id=d507e3468 href="http://dx.doi.org/10.1038/pr.2015.170">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725766912">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726172301"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3481 class=n-a></a>Janda A, Schwarz K, van der Burg M, <i> et al.</i>: Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome. <i>Blood.</i> 2016; <b>127</b>(18): 2193–202. <a target=xrefwindow id=d507e3492 href="http://www.ncbi.nlm.nih.gov/pubmed/26907631">PubMed Abstract </a> | <a target=xrefwindow id=d507e3495 href="http://dx.doi.org/10.1182/blood-2015-04-642488">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726172301">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d507e3508 class=n-a></a>Bleesing JJ, Straus SE, Fleisher TA: Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. <i>Pediatr Clin North Am.</i> 2000; <b>47</b>(6): 1291–310. <a target=xrefwindow id=d507e3516 href="http://www.ncbi.nlm.nih.gov/pubmed/11130997">PubMed Abstract </a> | <a target=xrefwindow id=d507e3519 href="http://dx.doi.org/10.1016/S0031-3955(05)70272-8 ">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727473691"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3528 class=n-a></a>Weinreich MA, Vogel TP, Rao VK, <i> et al.</i>: Up, Down, and All Around: Diagnosis and Treatment of Novel STAT3 Variant. <i>Front Pediatr.</i> 2017; <b>5</b>: 49. <a target=xrefwindow id=d507e3539 href="http://www.ncbi.nlm.nih.gov/pubmed/28349047">PubMed Abstract </a> | <a target=xrefwindow id=d507e3542 href="http://dx.doi.org/10.3389/fped.2017.00049">Publisher Full Text </a> | <a target=xrefwindow id=d507e3546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5347118">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727473691">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727688146"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3559 class=n-a></a>Nabhani S, Schipp C, Miskin H, <i> et al.</i>: <i>STAT3</i> gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds. <i>Clin Immunol.</i> 2017; <b>181</b>: 32–42. <a target=xrefwindow id=d507e3573 href="http://www.ncbi.nlm.nih.gov/pubmed/28579554">PubMed Abstract </a> | <a target=xrefwindow id=d507e3577 href="http://dx.doi.org/10.1016/j.clim.2017.05.021">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727688146">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d507e3591 class=n-a></a>Vignesh P, Rawat A, Singh S: An Update on the Use of Immunomodulators in Primary Immunodeficiencies. <i>Clin Rev Allergy Immunol.</i> 2017; <b>52</b>(2): 287–303. <a target=xrefwindow id=d507e3599 href="http://www.ncbi.nlm.nih.gov/pubmed/27873163">PubMed Abstract </a> | <a target=xrefwindow id=d507e3602 href="http://dx.doi.org/10.1007/s12016-016-8591-2">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d507e3611 class=n-a></a>Podjasek JC, Abraham RS: Autoimmune cytopenias in common variable immunodeficiency. <i>Front Immunol.</i> 2012; <b>3</b>: 189. <a target=xrefwindow id=d507e3619 href="http://www.ncbi.nlm.nih.gov/pubmed/22837758">PubMed Abstract </a> | <a target=xrefwindow id=d507e3622 href="http://dx.doi.org/10.3389/fimmu.2012.00189">Publisher Full Text </a> | <a target=xrefwindow id=d507e3625 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3402902">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d507e3634 class=n-a></a>Warnatz K, Voll RE: Pathogenesis of autoimmunity in common variable immunodeficiency. <i>Front Immunol.</i> 2012; <b>3</b>: 210. <a target=xrefwindow id=d507e3642 href="http://www.ncbi.nlm.nih.gov/pubmed/22826712">PubMed Abstract </a> | <a target=xrefwindow id=d507e3645 href="http://dx.doi.org/10.3389/fimmu.2012.00210">Publisher Full Text </a> | <a target=xrefwindow id=d507e3648 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3399211">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d507e3657 class=n-a></a>Miano M: How I manage Evans Syndrome and AIHA cases in children. <i>Br J Haematol.</i> 2016; <b>172</b>(4): 524–34. <a target=xrefwindow id=d507e3665 href="http://www.ncbi.nlm.nih.gov/pubmed/26625877">PubMed Abstract </a> | <a target=xrefwindow id=d507e3668 href="http://dx.doi.org/10.1111/bjh.13866">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d507e3677 class=n-a></a>Teachey DT, Manno CS, Axsom KM, <i> et al.</i>: Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). <i>Blood.</i> 2005; <b>105</b>(6): 2443–8. <a target=xrefwindow id=d507e3688 href="http://www.ncbi.nlm.nih.gov/pubmed/15542578">PubMed Abstract </a> | <a target=xrefwindow id=d507e3691 href="http://dx.doi.org/10.1182/blood-2004-09-3542">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d507e3700 class=n-a></a>Seif AE, Manno CS, Sheen C, <i> et al.</i>: Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. <i>Blood.</i> 2010; <b>115</b>(11): 2142–5. <a target=xrefwindow id=d507e3711 href="http://www.ncbi.nlm.nih.gov/pubmed/20068224">PubMed Abstract </a> | <a target=xrefwindow id=d507e3714 href="http://dx.doi.org/10.1182/blood-2009-08-239525">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d507e3724 class=n-a></a>Nomura K, Kanegane H, Otsubo K, <i> et al.</i>: Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. <i>Int J Hematol.</i> 2011; <b>93</b>(6): 760–4. <a target=xrefwindow id=d507e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/21626105">PubMed Abstract </a> | <a target=xrefwindow id=d507e3738 href="http://dx.doi.org/10.1007/s12185-011-0877-9">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d507e3747 class=n-a></a>Gobert D, Bussel JB, Cunningham-Rundles C, <i> et al.</i>: Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. <i>Br J Haematol.</i> 2011; <b>155</b>(4): 498–508. <a target=xrefwindow id=d507e3758 href="http://www.ncbi.nlm.nih.gov/pubmed/21981575">PubMed Abstract </a> | <a target=xrefwindow id=d507e3761 href="http://dx.doi.org/10.1111/j.1365-2141.2011.08880.x">Publisher Full Text </a> | <a target=xrefwindow id=d507e3765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3428031">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d507e3774 class=n-a></a>Shah S, Wu E, Rao VK, <i> et al.</i>: Autoimmune lymphoproliferative syndrome: an update and review of the literature. <i>Curr Allergy Asthma Rep.</i> 2014; <b>14</b>(9): 462. <a target=xrefwindow id=d507e3785 href="http://www.ncbi.nlm.nih.gov/pubmed/25086580">PubMed Abstract </a> | <a target=xrefwindow id=d507e3788 href="http://dx.doi.org/10.1007/s11882-014-0462-4">Publisher Full Text </a> | <a target=xrefwindow id=d507e3792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4148697">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d507e3801 class=n-a></a>Allison AC: Mechanisms of action of mycophenolate mofetil. <i>Lupus.</i> 2005; <b>14 Suppl 1</b>: s2–8. <a target=xrefwindow id=d507e3809 href="http://www.ncbi.nlm.nih.gov/pubmed/15803924">PubMed Abstract </a> | <a target=xrefwindow id=d507e3812 href="http://dx.doi.org/10.1177/096120330501400102">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d507e3821 class=n-a></a>Rao VK, Dugan F, Dale JK, <i> et al.</i>: Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. <i>Br J Haematol.</i> 2005; <b>129</b>(4): 534–8. <a target=xrefwindow id=d507e3832 href="http://www.ncbi.nlm.nih.gov/pubmed/15877736">PubMed Abstract </a> | <a target=xrefwindow id=d507e3835 href="http://dx.doi.org/10.1111/j.1365-2141.2005.05496.x">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d507e3844 class=n-a></a>Teachey DT, Jubelirer T, Baluarte HJ, <i> et al.</i>: Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. <i>Pediatr Blood Cancer.</i> 2009; <b>53</b>(6): 1114–6. <a target=xrefwindow id=d507e3855 href="http://www.ncbi.nlm.nih.gov/pubmed/19621445">PubMed Abstract </a> | <a target=xrefwindow id=d507e3858 href="http://dx.doi.org/10.1002/pbc.22183">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d507e3868 class=n-a></a>Battaglia M, Stabilini A, Migliavacca B, <i> et al.</i>: Rapamycin promotes expansion of functional CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells of both healthy subjects and type 1 diabetic patients. <i>J Immunol.</i> 2006; <b>177</b>(12): 8338–47. <a target=xrefwindow id=d507e3889 href="http://www.ncbi.nlm.nih.gov/pubmed/17142730">PubMed Abstract </a> | <a target=xrefwindow id=d507e3892 href="http://dx.doi.org/10.4049/jimmunol.177.12.8338">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d507e3901 class=n-a></a>Battaglia M, Stabilini A, Roncarolo M: Rapamycin selectively expands CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells. <i>Blood.</i> 2005; <b>105</b>(12): 4743–8. <a target=xrefwindow id=d507e3919 href="http://www.ncbi.nlm.nih.gov/pubmed/15746082">PubMed Abstract </a> | <a target=xrefwindow id=d507e3922 href="http://dx.doi.org/10.1182/blood-2004-10-3932">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727345252"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3931 class=n-a></a>Cayrol J, Garrido Colino C: Use of Sirolimus (Rapamycin) for Treatment of Cytopenias and Lymphoproliferation Linked to Autoimmune Lymphoproliferative Syndrome (ALPS). Two Case Reports. <i>J Pediatr Hematol Oncol.</i> 2017; <b>39</b>(4): e187–e190. <a target=xrefwindow id=d507e3939 href="http://www.ncbi.nlm.nih.gov/pubmed/28234735">PubMed Abstract </a> | <a target=xrefwindow id=d507e3942 href="http://dx.doi.org/10.1097/MPH.0000000000000785">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727345252">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725548067"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e3955 class=n-a></a>Miano M, Scalzone M, Perri K, <i> et al.</i>: Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience. <i>Br J Haematol.</i> 2015; <b>171</b>(2): 247–253. <a target=xrefwindow id=d507e3966 href="http://www.ncbi.nlm.nih.gov/pubmed/26058843">PubMed Abstract </a> | <a target=xrefwindow id=d507e3969 href="http://dx.doi.org/10.1111/bjh.13533">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725548067">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d507e3982 class=n-a></a>Rao VK, Price S, Perkins K, <i> et al.</i>: Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). <i>Pediatr Blood Cancer.</i> 2009; <b>52</b>(7): 847–52. <a target=xrefwindow id=d507e3993 href="http://www.ncbi.nlm.nih.gov/pubmed/19214977">PubMed Abstract </a> | <a target=xrefwindow id=d507e3996 href="http://dx.doi.org/10.1002/pbc.21965">Publisher Full Text </a> | <a target=xrefwindow id=d507e4000 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2774763">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d507e4009 class=n-a></a>Calvo KR, Price S, Braylan RC, <i> et al.</i>: JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. <i>Blood.</i> 2015; <b>125</b>(18): 2753–8. <a target=xrefwindow id=d507e4020 href="http://www.ncbi.nlm.nih.gov/pubmed/25691160">PubMed Abstract </a> | <a target=xrefwindow id=d507e4023 href="http://dx.doi.org/10.1182/blood-2014-11-567917">Publisher Full Text </a> | <a target=xrefwindow id=d507e4027 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4424627">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d507e4037 class=n-a></a>Cerutti E, Campagnoli MF, Ferretti M, <i> et al.</i>: Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. <i>BMC Immunol.</i> 2007; <b>8</b>: 28. <a target=xrefwindow id=d507e4048 href="http://www.ncbi.nlm.nih.gov/pubmed/17999750">PubMed Abstract </a> | <a target=xrefwindow id=d507e4051 href="http://dx.doi.org/10.1186/1471-2172-8-28">Publisher Full Text </a> | <a target=xrefwindow id=d507e4055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2211507">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d507e4064 class=n-a></a>Clementi R, Dagna L, Dianzani U, <i> et al.</i>: Inherited perforin and <i>Fas</i> mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. <i>N Engl J Med.</i> 2004; <b>351</b>(14): 1419–24. <a target=xrefwindow id=d507e4078 href="http://www.ncbi.nlm.nih.gov/pubmed/15459303">PubMed Abstract </a> | <a target=xrefwindow id=d507e4082 href="http://dx.doi.org/10.1056/NEJMoa041432">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d507e4091 class=n-a></a>Clementi R, Chiocchetti A, Cappellano G, <i> et al.</i>: Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. <i>Blood.</i> 2006; <b>108</b>(9): 3079–84. <a target=xrefwindow id=d507e4102 href="http://www.ncbi.nlm.nih.gov/pubmed/16720836">PubMed Abstract </a> | <a target=xrefwindow id=d507e4105 href="http://dx.doi.org/10.1182/blood-2006-02-001412">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1010062"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e4114 class=n-a></a>Chun HJ, Zheng L, Ahmad M, <i> et al.</i>: Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. <i>Nature.</i> 2002; <b>419</b>(6905): 395–9. <a target=xrefwindow id=d507e4125 href="http://www.ncbi.nlm.nih.gov/pubmed/12353035">PubMed Abstract </a> | <a target=xrefwindow id=d507e4128 href="http://dx.doi.org/10.1038/nature01063">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1010062">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d507e4141 class=n-a></a>Bolze A, Byun M, McDonald D, <i> et al.</i>: Whole-exome-sequencing-based discovery of human FADD deficiency. <i>Am J Hum Genet.</i> 2010; <b>87</b>(6): 873–81. <a target=xrefwindow id=d507e4152 href="http://www.ncbi.nlm.nih.gov/pubmed/21109225">PubMed Abstract </a> | <a target=xrefwindow id=d507e4155 href="http://dx.doi.org/10.1016/j.ajhg.2010.10.028">Publisher Full Text </a> | <a target=xrefwindow id=d507e4159 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2997374">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d507e4168 class=n-a></a>Oliveira JB: The expanding spectrum of the autoimmune lymphoproliferative syndromes. <i>Curr Opin Pediatr.</i> 2013; <b>25</b>(6): 722–9. <a target=xrefwindow id=d507e4176 href="http://www.ncbi.nlm.nih.gov/pubmed/24240292">PubMed Abstract </a> | <a target=xrefwindow id=d507e4179 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4435794">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718156954"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d507e4189 class=n-a></a>Lucas CL, Kuehn HS, Zhao F, <i> et al.</i>: Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. <i>Nat Immunol.</i> 2014; <b>15</b>(1): 88–97. <a target=xrefwindow id=d507e4200 href="http://www.ncbi.nlm.nih.gov/pubmed/24165795">PubMed Abstract </a> | <a target=xrefwindow id=d507e4203 href="http://dx.doi.org/10.1038/ni.2771">Publisher Full Text </a> | <a target=xrefwindow id=d507e4207 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4209962">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718156954">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d507e4220 class=n-a></a>Azizi G, Pouyani MR, Abolhassani H, <i> et al.</i>: Cellular and molecular mechanisms of immune dysregulation and autoimmunity. <i>Cell Immunol.</i> 2016; <b>310</b>: 14–26. <a target=xrefwindow id=d507e4231 href="http://www.ncbi.nlm.nih.gov/pubmed/27614846">PubMed Abstract </a> | <a target=xrefwindow id=d507e4234 href="http://dx.doi.org/10.1016/j.cellimm.2016.08.012">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 01 Nov 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1928&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1928&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Oncology, The Children&rsquo;s Hospital of Philadelphia, Philadelphia, PA, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-1928/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 01 Nov 2017, 6:1928 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11545.1">https://doi.org/10.12688/f1000research.11545.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Bride K and Teachey D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12471 data-id=11545 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11545.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-1928/v1/pdf?article_uuid=9a6f9850-4203-4481-9072-bb8039743b55" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11545.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bride K and Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1928 (<a href="https://doi.org/10.12688/f1000research.11545.1" target=_blank>https://doi.org/10.12688/f1000research.11545.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11545 id=mobile-track-article-signin-11545 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11545?target=/articles/6-1928"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12471 /> <input name=articleId type=hidden value=11545 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Fr&eacute;d&eacute;ric Rieux-Laucat</strong>, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute INSERM UMR1163, University Paris Descartes, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Luis M. Allende</strong>, Immunology Department, Hospital 12 de Octubre, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ugo Ramenghi</strong>, University of Torino, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 01 Nov 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1928&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1928&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=26913-27480></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=26914-27481></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=26915-27484></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-1928/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>01 Nov 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Fr&eacute;d&eacute;ric Rieux-Laucat</strong>, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute INSERM UMR1163, University Paris Descartes, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Luis M. Allende</strong>, Immunology Department, Hospital 12 de Octubre, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ugo Ramenghi</strong>, University of Torino, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-1928&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-1928/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Autoimmune lymphoproliferative syndrome:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-1928/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-1928/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-1928/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bride K and Teachey D');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-1928/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-1928",
            templates : {
                twitter : "Autoimmune lymphoproliferative syndrome: more than a FAScinating.... Bride K and Teachey D, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-1928/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Autoimmune lymphoproliferative syndrome: more than a FAScinating disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Autoimmune lymphoproliferative syndrome: more than a FAScinating disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11545/12471")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12471");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "27480": 0,
                           "27481": 0,
                           "27482": 0,
                           "27483": 0,
                           "27484": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c903dfea-4a34-4a13-b524-38ff3b9768ac";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1928.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1928.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1928.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-1928.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-1928.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>